業績一覧

講　演

Finn RS, Kelley RK, Furuse J, Edeline J, Ren Z, Su SC, Malhotra U, Siegel AB, Valle JW: KEYNOTE-966 : A randomized, double-blind, placebo-controlled, phase 3 study of pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract carcinoma. AACR. Online. April 24th,.2020.
Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, He Y, Soni N, Benhadji KA, Bridgewater JA: FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. 2020 ASCO Annual Meeting. Online. May 28th-31st. 2020.
Ohba A, Nakamura Y,Taniguchi H, Ikeda M, Bando H, Mizuno N, Kato K, Morizane C, Nishina T, Ueno M, Furuse J, Hara H, Denda T, Kawakami H, Esaki T, Moriwaki T, Yasui H, Komatsu Y, Yoshino T, Ohtsu A: Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (pts) with advanced non-colorectal (non-CRC) gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis. 2020 ASCO Annual Meeting. Online. May 28th-31st. 2020.
Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Ogawa G, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T: Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. 2020 ASCO Annual Meeting. Online. May 28th-31st. 2020.
Park W, O’Reilly EM, Furuse J, Kunieda F, Jie F, Kindler HL: Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2–positive metastatic pancreatic cancer (mPC). 2020 ASCO Annual Meeting. Online. May 28th-31st. 2020.
Nakamura Y, Taniguchi H, Bando H, Esaki T, Komatsu Y, Kato K, Takahashi N, Kagawa Y, Kato T, Nishina T, Satoh T, Oki E, Sunakwa Y, Ueno M, Yamamoto Y, Kawakami H, Denda T, Furuse J, Ohtsu A, Yoshino T: Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients (pts) with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis. Poster Discussion abstr #4071. Annual meeting of American Society of Clinical Oncology (ASCO) 2020. Online. May 29th.2020.
Ohba A, Nakamura Y, Taniguchi H, Ikeda M, Bando H, Mizuno N, Kato K, Morizane C, Nishina T, Ueno M, Furuse J, Hara H, Denda T, Kawakami H, Esaki T, Moriwaki T, Yasui H, Komatsu Y, Yoshino T, Ohtsu A: Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (pts) with advanced non-colorectal (non-CRC) gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis. Poster Discussion abstr #3516. Annual meeting of American Society of Clinical Oncology (ASCO) 2020. Online. May 29th. 2020.
Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Ogawa G, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T : Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2 positive unresectable or recurrent biliary tract cancer — HERB trial. General Poster abstr #TPS4654. Annual meeting of American Society of Clinical Oncology (ASCO) 2020. Online. May 29th. 2020.
Park W, O’Reilly EM, Furuse J, Kunieda F, Jie F, Kindler HL: Phase II, Open-Label, Randomized Study of First-line Zolbetuximab Plus Gemcitabine and Nab-Paclitaxel (GN) in Claudin 18.2–Positive Metastatic Pancreatic Cancer (mPC). General Poster abstr #TPS4667. Annual meeting of American Society of Clinical Oncology (ASCO) 2020. Online. May 29th.2020.
Akihiro Ohba, Chigusa Morizane, Makoto Ueno, Satoshi Kobayashi, Yasuyuki Kawamoto, Yoshito Komatsu, Masafumi Ikeda, Mitsuhito Sasaki, Naohiro Okano, Junji Furuse, Nobuyoshi Hiraoka, Hiroshi Yoshida, Aya Kuchiba, Gakuto Ogawa, Kenichi Nakamura, Naoko Matsui, Yoshiaki Nakamura, Wataru Okamoto, Takayuki Yoshino, Takuji Okusaka : Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Annual meeting of American Society of Clinical Oncology (ASCO) 2020. Online. May 28th-31st. 2020.
Vogel A, Finn RS, Kelley RK, Furuse J, Edeline J, Ren Z, Su SC, Malhotra U, Abby B. Siegel AB, Valle JW : Pembrolizumab in Combination With Gemcitabine and Cisplatin for the Treatment of Advanced Biliary Tract Cancer: Phase 3 KEYNOTE-966 Trial in Progress. ESMO World Congress on Gastrointestinal cancer 2020. Online. July 1st-4th. 2020.
長島文夫：高齢がん患者の治療選択について考える. 山口大学講演会．オンライン．2020年7月21日．
Borad MJ, Bridgewater JA, Morizane C, Shroff RT, Oh DY, Moehler M, Furuse J, Benhadji KA, He Y, Valle JW : An open-label, randomized phase 3 study of futibatinib (TAS-120) versus gemcitabine-cisplatin chemotherapy as first-line treatment for patients with advanced cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene rearrangements (FOENIX-CCA3). Cholangiocarcinoma Foundation． Online． July 22th． 2020.
長島文夫：高齢者のがん薬物療法ガイドライン.第62回日本老年医学会学術集会．オンライン．2020年8月4日‐6日.
Izumi N, Kudo M, Kato N, Hagihara A, Numata K, Aikata H, Inaba Y, Motomura K, Furuse J, Ikeda M, Morimoto M, Kuroda S, Kimura A: Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: A Phase II multicenter study (Cabozantinib-2003).第56回日本肝臓学会．オンライン．2020年8月28日．
長島文夫：高齢者がん薬物療法の考え方.桜山がん診療包括ケアカンファレンス．オンライン名古屋Web ．2020年9月3日．
Furuse J : PC-Cure-1: a retrospective study of Conversion Surgery for unresectable Pancreatic Cancer. Update of FACO Clinical Trials. 13th Annual Meeting of the Korean Society of Medical Oncology & 2020 International Conference (KSMO 2020), 8th International Conference of the Federation of Asian Clinical Oncology (FACO)．Online． Sep 4th．2020.
Kelly RK, Vogel A, Finn RS, Furuse J, Edeline J, Ren Z, Su SC, Malhotra U, Siege AB, Valle JW: Pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract cancer : Phase 3 KEYNOTE-966 trial in progress. International Liver Cancer Association 2020.Online. Sep 11th. 2020.
Furuse J : Pancreatic canc.er treatments Asian perspective. Joining efforts across the borders in improving mPDAC patient outcomesSymposium organized by Servier. ESMO2020.Online. Sep 18th. 2020.
古瀬純司：肝胆膵領域がんにおける最近の動向．会長企画シンポジウム 2 ASCO2020、ESMO2020の総括と新たな診療の構築1 －消化管・肝胆膵・呼吸器・頭頸部－．第58回日本癌治療学会学術集会．京都．2020年10月22日．
長島文夫：高齢がんにおけるウェアラブルデバイスを用いた生体情報採録システムの実施可能性試験．第58回日本癌治療学会学術集会．京都．2020年10月22日．
Furuse J, Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Kelley RK, Cassier PA, Klümpen HJ, Uboha NV, Mahipal A, Mitchell E, Ahn E, Chang HM, Masuda K, He Y, Benhadji KA, Bridgewater JA: Efficacy, Safety, and Quality of Life With Futibatinib in Patients With Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements: FOENIX-CCA2. Mini Oral Session. ESMO-Asia 2020. Online. Nov 20th. 2020.
古瀬純司：膵がん化学療法の最新情報－オニバイド®（nal-IRI)を中心に. 新潟消化管研究会．新潟．2020年10月17日．
古瀬純司：膵がん化学療法の最新情報－オニバイド®（nal-IRI)を中心に．新潟消化管研究会. 仙台．2020年11月13日．
長島文夫：高齢者大腸がん患者における現状と課題. 高齢者がん患者に関わる多職種連携セミナー．オンライン東京Web ．2020年11月17日．
古瀬純司：肝癌におけるがんサポーティブケア．第56回日本肝癌研究会．オンライン．2020年12月23日.
古瀬純司：特別発言．パネルディスカッション 3 切除不能膵癌に対する集学的治療．第51回日本膵臓学会大会．オンライン．2021年1月8日．
古瀬純司：ランチョンセミナー 4. 膵癌の薬物療法最前線~2次治療を見据えた治療戦略．第51回日本膵臓学会大会．オンライン．2021年1月8日．
古瀬純司：教育セミナー．膵癌薬物療法．第51回日本膵臓学会大会．オンライン．2021年1月8日．
Kudo M, Ueshima K, Ikeda M, Torimura T, Aikata H, Izumi N, Yamasaki T, Hino K, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yoshimura K, Okusaka T, Furuse J, Arai Y: TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC). Gastrointestinal Cancers Symposium 2021. Online. January 15th-17th.2021.
Okano N, Morizane C, Okusaka T, Sadachi R, Kataoka T, Ueno M, Ikeda M, Ozaka M, Sugimori K, Todaka A, Shimizu S, Mizuno N, Yamamoto T, Sano K, Tobimatsu K, Katanuma A, Miyamoto A, Yamaguchi H, Ishii H, Furuse J : Analysis of early tumor shrinkage and depth of response in patients with advanced biliary tract cancer treated with gemcitabine plus cisplatin or gemcitabine plus S-1: An exploratory analysis of JCOG1113. Gastrointestinal Cancers Symposium 2021. Online. January 15th-17th.2021.
McNamara MG, Bridgewater JA, Goyal L, Goldstein D, Shroff RT, Moehler MH, Lowery MA, Bekaii-Saab TS, Kelley RK, Furuse J, Rimassa L, Morizane C, Lamarca A, Hubner R, Knox JJ, Valle JW: Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC). Gastrointestinal Cancers Symposium 2021. Online. January 15th-17th.2021.
Suzuki E, Morizane C, Ogawa G, Kataoka T, Okano N, Okusaka T, Ueno M, Ikeda M, Ozaka M, Sugimori K, Todaka A, Shimizu S, Mizuno N, Yamamoto T, Sano K, Tobimatsu K, Katanuma A, Miyamoto A, Fukuda H, Ishii H, Furuse J: Impact of liver cirrhosis in patients with intrahepatic cholangiocarcinoma receiving systemic chemotherapy: a subgroup analysis of the JCOG1113 randomized phase III trial. Poster # J-16, The Asian Pacific Association for the Study of the Liver (APASL) 2021. Online. Feb 4th-6th. 2021.
上野誠，森實千種，井岡達也，田近正洋，池田公史，山口研成，原浩樹，薮崎裕，宮本敦史，岩佐悟，武藤学，高島勉，三梨桂子，小松嘉人，仁科智裕，中島貴子，佐原貴寿，上原泰介，船坂勢津雄，八代正和，古瀬純司: Clinical update with genomic analyses in expansion part of phase 1 study of selective FGFR inhibitor E7090. MO38-3．第18回日本臨床腫瘍学会学術集会．オンライン．2021年2月18日‐21日．
Ogasawara S, Yamashita T, Kurosaki M, Numata K, Morimoto N, Ohkawa K, Arakawa T, Manabu Morimoto M, Muromatsu R, Ishigami M, Furuse J, Ogawa K, Hiroshi Aikata H, Hasegawa K, Sawako U, Tsutomu Takatsuki T, Yoshida T, Han S, Malhotra U, Kudo M: Effect of pembrolizumab on hepatitis viral load and ALT levels in Japanese patients with hepatocellular carcinoma．第18回日本臨床腫瘍学会学術集会．オンライン．2021年2月18日‐21日．
Oh DY, Braud FD, Bridgewater J, Furuse J, Hsu CH, Ikeda M, Lee S, Moehler M, Park JO, Shen L, Yoo C, Helwig C, Osada M, Borad M: Phase 2/3 study of bintrafusp alfa with gemc-itabine plus cisplatin as first-line treatment of bil-iary tract cancer．第18回日本臨床腫瘍学会学術集会．オンライン．2021年2月18日‐21日．
今岡大，池田公史，前原耕介，梅本久美子，尾阪将人，小林智，寺島健志，井上博登，坂口智紘，辻国広，塩路和彦，岡村圭也，川本泰之，鈴木玲，白川博文，永野浩昭，上野誠，森實千種，古瀬純司：Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas．第18回日本臨床腫瘍学会学術集会．オンライン．2021年2月18日‐21日．
木村綾，福田治彦，中村健一，柴田大朗，江場淳子，片岡智子，山本精一郎，水谷友紀，上野誠，枝園忠彦，小島崇宏，吉川貴己，丸山大，古瀬純司：JCOGにおける患者・市民参画の取り組み．第18回日本臨床腫瘍学会学術集会．オンライン．2021年2月18日‐21日．
Satoshi Yuki, Yoshiaki Nakamura, Hiroya Taniguchi, Tadamichi Denda, Tomohiro Nishina, Yasuo Hamamoto, Hiroki Hara, Taito Esaki, Hisato Kawakami, Atsuo Takashima, Taroh Satoh, Yu Sunakawa, Toshiki Masuishi, Eiji Shinozaki, Toshikazu Moriwaki, Izumi Miki, Kohei Shitara, Takayuki Yoshino : Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC．第18回日本臨床腫瘍学会学術集会．オンライン．2021年2月18日‐21日．
長島文夫：SIOG-JSMO joint symposium 第3期がん対策推進基本計画における今後の課題と持続可能な社会として目指すもの．第18回日本臨床腫瘍学会学術集会．2021年2月18日‐20日．
古瀬純司：大きく変わった肝細胞がんの薬物療法.－免疫チェックポイント阻害の時代へ．西東京市医師会学術講演会．オンライン．2021年1月19日．
長島文夫：高齢者に対するがん薬物療法．第17回日本消化管学会総会学術集会．オンライン． 2021年2月19日‐21日．
古瀬純司: がん悪液質とアナモレリン（エドルミズ錠®）のエビデンス. 最新医療研究会. オンライン. 2021年2月25日．
古瀬純司：特別講演. 切除不能膵癌におけるconversion surgeryの動向．第49回九州膵研究会．オンライン．2021年3月6日．
長島文夫：AMEDロボット介護機器開発・標準化事業（効果測定・評価事業）成果報告会．オンライン． 2021年3月27日.

論　文

欧文

Okano N, Furuse J, Ueno M¹, Morizane C², Yamanaka T³, Ojima H⁴, Ozaka M⁵, Sasaki M⁶, Takahara N⁷, Nakai Y⁷, Kobayashi S¹, Morimoto M¹, Hosoi H², Maeno S, Nagashima F, Ikeda M⁸, Okusaka T² (¹Kanagawa Cancer Center, ²National Cancer Center Hospital,³Yokohama City University School of Medicine, ⁴Keio University School of Medicine, ⁵The Cancer Institute of JFCR, ⁶National Cancer Center Hospital East, ⁷The University of Tokyo) : Multicenter phase II trial of axitinib monotherapy for gemcitabine-based chemotherapy refractory advanced biliary tract cancer (AX-BC Study). Oncologist. 2020. DOI: 10.1002/onco.13547. [Epub]
Ueno M¹, Nakamori S², Sugimori K³, Kanai M⁴, Ikeda M⁵, Ozaka M⁶, Furukawa M⁷, Okusaka T⁸, Kawabe K⁹, Furuse J, Komatsu Y¹⁰, Ishii H¹¹, Sato A¹², Shimizu S¹³, Chugh P¹⁴, Tang R¹⁵, Ioka T¹⁶. (¹Kanagawa Cancer Center, ²NHO Osaka National Hospital, ³Yokohama City University Medical Center, ⁴Kyoto University Hospital, ⁵National Cancer Center Hospital East, ⁶Cancer Institute Hospital of JFCR , ⁷NHO Kyushu Cancer Center, ⁸National Cancer Center Hospital, ⁹Kyushu University,¹⁰Hokkaido University Hospital Cancer Center,¹¹Chiba Cancer Center, ¹²Hirosaki University Hospital, ¹³Saitama Cancer Center , ¹⁴Servier Pharmaceuticals , ¹⁵Osaka International Cancer Institute) : nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Cancer Med. 9(24). 9396-9408. 2020.
Nara S¹, Esaki M¹, Ban D¹, Takamoto T¹, Shimada K¹, Ioka T², Okusaka T³, Ishii H⁴, Furuse J (¹National Cancer Center Hospital, ²Yamaguchi University Graduate School of Medicine, ³National Cancer Center Hospital, ⁴Chiba Cancer Center) : Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials. Jpn J Clin Oncol. 50(12).1353-1363. 2020.
Nakamura Y¹, Taniguchi H¹, Ikeda M¹, Bando H², Kato K³, Morizane C³, Esaki T⁴, Komatsu Y⁵, Kawamoto Y⁶, Takahashi N⁷, Ueno M⁸, Kagawa Y⁹, Nishina T¹⁰, Kato T¹¹, Yamamoto Y¹², Furuse J, Denda T¹³, Kawakami H¹⁴, Oki E¹⁵, Nakajima T¹⁶, Nishida N¹⁷, Yamaguchi K¹⁸, Yasui H¹⁹, Goto M²⁰, Matsuhashi N²¹, Ohtsubo K²², Yamazaki K²³, Tsuji A²⁴, Okamoto W^1,25, Tsuchihara K^1,26, Yamanaka T¹, Miki I¹, Sakamoto Y¹, Ichiki H¹, Hata M¹, Yamashita R²⁶, Ohtsu A¹, Odegaard JI²⁷, Yoshino T¹(¹ National Cancer Center Hospital East, ²National Cancer Center Hospital East, ³Aichi Cancer Center Hospital,⁴National Cancer Center Hospital, ⁵National Hospital Organization Kyushu Cancer Center, ⁶Hokkaido University Hospital, ⁷Saitama Cancer Center, ⁸Kanagawa Cancer Center, ⁹Kansai Rosai Hospital, ¹⁰National Hospital Organization Shikoku Cancer Center, ¹¹National Hospital Organization Osaka National Hospital, ¹²University of Tsukuba Hospital, ¹³Chiba Cancer Center, ¹⁴Kindai University Hospital, ¹⁵Kyushu University, ¹⁶St. Marianna University School of Medicine, ¹⁷Osaka University, ¹⁸Cancer Institute Hospital of Japanese Foundation for Cancer Research, ¹⁹Kobe City Medical Center General Hospital, ²⁰Osaka Medical College Hospital, ²¹Gifu University, ²²Kanazawa University, ²³Shizuoka Cancer Center, ²⁴Kagawa University Hospital, ²⁵Hiroshima University Hospital,²⁶National Cancer Center, ²⁷Guardant Health, Redwood City) : Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. 26(12). 1859-1864. 2020.
Okuyama H^1,2, Ikeda M², Okusaka T³, Furukawa M⁴, Ohkawa S⁵, Hosokawa A⁶, Kojima Y⁷, Hara H⁸, Murohisa G⁹, Shioji K¹⁰, Asagi A¹¹, Mizuno N¹², Kojima M¹³, Yamanaka T¹⁴ (¹Kagawa University, ²National Cancer Center Hospital East, ³National Cancer Center Hospital, ⁴National Hospital Organization Kyushu Cancer Center, ⁵Kanagawa Cancer Center,⁶Faculty of Medicine University of Toyama, Toyama, ⁷National Center for Global Health and Medicine, ⁸Saitama Cancer Center, ⁹Seirei Hamamatsu General Hospital, ¹⁰Niigata Cancer Center Hospital, ¹¹National Hospital Organization Shikoku Cancer Center, ¹²Aichi Cancer Center Hospital, ¹³Exploratory Oncology Research and Clinical Trial Center, ¹⁴Yokohama City University Graduate School of Medicine) : A phase II trial of everolimus in patients with advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy (NECTOR trial). Neuroendocrinology. 110(11-12). 988-993. 2020.
Tanaka H¹, Hijioka S², Hosoda W³, Ueno M⁴, Kobayashi N⁵, Ikeda M⁶, Ito T⁷, Kodama Y⁸, Morizane C⁹, Notohara K¹⁰, Taguchi H¹¹, Kitano M¹², Komoto I¹³, Tsuji A¹⁴, Hashigo S¹⁵, Kanno A¹⁶, Miyabe K¹⁷, Takagi T¹⁸, Ishii H, Kojima Y¹⁹, Yoshitomi H²⁰, Yanagimoto H²¹, Mizuno N³ (¹Suzuka General Hospital, ²National Cancer Center Hospital, ³Aichi Cancer Center Hospital, ⁴Kanagawa Cancer Center,⁵Yokohama City University Hospital, ⁶National Cancer Center Hospital East,⁷Fukuoka Sannno Hospital, ⁸Kobe University Graduate School of Medicine, ⁹National Cancer Center Hospital, ¹⁰Kurashiki Central Hospital, ¹¹Saiseikai Sendai Hospital, ¹²Wakayama Medical University, ¹³Kansai Electric Power Hospital, ¹⁴Kagawa University, ¹⁵Kumamoto University, ¹⁶Tohoku University Graduate School of Medicine, ¹⁷Japanese Red Cross Nagoya Daini Hospital, ¹⁸Fukushima Medical University School of Medicine, ¹⁹Chiba Cancer Center, ²⁰Center Hospital of the National Center for Global Health and Medicine, ²¹Chiba University, ²²Kobe University Graduate School of Medicine) : Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. Pancreatology. 20(7). 1421-1427. 2020.
Bekaii-Saab TS¹, Valle JW², Cutsem EV³, Rimassa L^4,5, Furuse J, Ioka T⁶, Melisi D⁷, Macarulla T⁸, Bridgewater J⁹, Wasan H¹⁰, Borad MJ¹, Abou-Alfa GK^11,12, Jiang P¹³, Lihou CF¹³, Zhen H¹³, Asatiani E¹⁴, Féliz L¹⁴, Vogel A¹⁵ (¹Mayo Clinic, ²University of Manchester , The Christie Hospital NHS Foundation Trust, The University of Manchester, ³University of Leuven, ⁴Humanitas Clinical and Research Center-IRCCS, ⁵Humanitas University, ⁷Osaka International Cancer Institute, ⁸University of Verona, ⁹Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, ¹⁰UCL Cancer Institute, University College London, ¹¹Hammersmith Hospital, Imperial College Health Care Trust, ¹²Memorial Sloan Kettering Cancer Center, ¹³Weill Medical College, Cornell University, ¹⁴Incyte Corporation, Wilmington, ¹⁵Incyte Biosciences International Sàrl, Morges, ¹⁶Hannover Medical School) : FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 16(30). 2385-2399. 2020.
Okano N, Hana K¹, Naruge D, Kawai K, Kobayashi T, Nagashima F, Endou H¹, Furuse J : (¹J-Pharma Co) : Biomarker analyses in patients with advanced solid tumors treated with the LAT1 Inhibitor JPH203. In Vivo. 34(5). 2595-2606. 2020.
Kudo M¹, Morimoto M², Moriguchi M³, Izumi N⁴, Takayama T⁵, Yoshiji H⁶, Hino K⁷, Oikawa T⁸, Chiba T⁹, Motomura K¹⁰, Kato J¹¹, Yasuchika K¹², Ido A¹³, Sato T¹⁴, Nakashima D¹⁴, Ueshima K¹, Ikeda M¹⁵, Okusaka T¹⁶, Tamura K¹⁷, Furuse J (¹Kindai University, ²Kanagawa Cancer Center, ³Kyoto Prefectural University of Medicine, ⁴Musashino Red Cross Hospital, ⁵Tokushima University Graduate School of Biomedical Sciences, ⁶Nara Medical University, ⁷Kawasaki Medical School, ⁸Iwate Medical University, ⁹Chiba University, ¹⁰Aso Iizuka Hospital, ¹¹Juntendo University School of Medicine, ¹²Kyoto University Graduate School of Medicine, ¹³Kagoshima University Medical and Dental Hospital, ¹⁴Kyowa Kirin Co., ¹⁵National Cancer Center Hospital East, ¹⁶National Cancer Center Hospital, ¹⁷Fukuoka University) : A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. Cancer Sci. 111(10). 3759-69. 2020.
Imaoka H¹, Ikeda M¹, Maehara K², Umemoto K³, Ozaka M⁴, Kobayashi S⁵, Terashima T⁶, Inoue H⁷, Sakaguchi C⁸, Tsuji K⁹, Shioji K¹⁰, Okamura K¹¹, Kawamoto Y¹², Suzuki R¹³, Shirakawa H¹⁴, Nagano H¹⁵, Ueno M⁵, Morizane C², Furuse J (¹National Cancer Center Hospital East, ²National Cancer Center Hospital , ³St.Marianna University School of Medicine , ⁴Cancer Institute Hospital Japanese Foundation for Cancer Research , ⁵Kanagawa Cancer Center ,⁶Kanazawa University Hospital ,⁷Shizuoka Cancer Center ,⁸Shikoku Cancer Center ,⁹Ishikawa Prefectural Central Hospital, ¹⁰Niigata Cancer Center Hospital ,¹¹JA Sapporo Kohsei Hospital ,¹²Hokkaido University Hospital, ¹³Fukushima Medical University School of Medicine ,¹⁴Tochigi Cancer Center ,¹⁵Yamaguchi University Graduate School of Medicine ) : Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a
Okano N, Morizane C¹, Nomura S², Takahashi H³, Tsumura H⁴, Satake H⁵, Mizuno N⁶, Tsuji K⁷, Shioji K⁸, Asagi A⁹, Yasui K¹⁰, Kitagawa S¹¹, Kashiwada T¹², Ishiguro A¹³, Kanai M¹⁴, Ueno M¹⁵, Ogura T¹⁶, Shimizu S¹⁷, Tobimatsu K¹⁸, Motoya M¹⁹, Nakashima K²⁰, Ikeda M³, Okusaka T¹, Furuse J (¹National Cancer Center Hospital, ²National Cancer Center, ³National Cancer Center Hospital East,⁴Hyogo Cancer Center, ⁵Kobe City Medical Center General Hospital,⁶Aichi Cancer Center Hospital,⁷Ishikawa Prefectural Central Hospital,⁸Niigata Cancer Center Hospital,⁹National Hospital Organization Shikoku Cancer Center,¹⁰Kyoto Prefectural University of Medicine,¹¹Sapporo Kosei General Hospital, ¹²Saga University, ¹³Teine Keijinkai Hospital,¹⁴Kyoto University,¹⁵Kanagawa Cancer Center, ¹⁶St. Marianna University School of Medicine, ¹⁷Saitama Cancer Center,¹⁸Kobe University Graduate School of Medicine,¹⁹Sapporo Medical University School of Medicine,²⁰University of Miyazaki Hospital) : Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). Int J Clin Oncol. 25(10). 1835-1843. 2020.
Okano N, Naruge D, Kawai K, Kobayashi T, Nagashima F, Endou H¹, Furuse J (¹J-Pharma Co) : First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Invest New Drugs. 38(5). 1495-1506. 2020.
Kudo M¹, Ueshima K¹, Ikeda M², Torimura T³, Tanabe N⁴, Aikata H⁵, Izumi N⁶, Yamasaki T⁷, Nojiri S⁸, Hino K⁹, Tsumura H¹⁰, Kuzuya T¹¹, Isoda N¹², Yasui K¹³, Aino H¹⁴, Ido A¹⁵, Kawabe N¹⁶, Nakao K¹⁷, Wada Y¹⁸, Yokosuka O¹⁹, Yoshimura K²⁰, Okusaka T²¹, Furuse J, Kokudo N²², Okita K²³, Johnson PJ²⁴, Arai Y²¹; TACTICS study group (¹Kindai University Faculty of Medicine,²National Cancer Center Hospital East,³Kurume University School of Medicine, ⁴National Hospital Organisation Sendai Medical Center,⁵Hiroshima University,⁶Musashino Red Cross Hospital,⁷Yamaguchi University Graduate School of Medicine,⁸Nagoya City University Graduate School of Medical Sciences,⁹Kawasaki Medical School,¹⁰Hyogo Cancer Center,¹¹Nagoya University Graduate School of Medicine,¹²Jichi Medical University,¹³Kyoto Prefectural University of Medicine,¹⁴Social Insurance Tagawa Hospital,¹⁵Kagoshima University Graduate School of Medical and Dental Sciences,¹⁶Fujita Health University School of Medicine,¹⁷Nagasaki University Graduate School of Biomedical Sciences,¹⁸National Hospital Organization Kyushu Medical Center,¹⁹Chiba University,²⁰Hiroshima University,²¹National Cancer Center Hospital,²²National Center for Global Health and Medicine,²³Shunan Memorial Hospital, ²⁴University of Liverpool) : Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 69(8). 1492-1501. 2020.
Ikeda M¹, Morizane C², Hijioka S³, Matsumoto S⁴, Konishi T⁵, Komoto I⁶, Aoki T⁷, Ito T⁸, Furuse J, Sasano H⁹, Doi R¹⁰ (¹National Cancer Center Hospital East,²National Cancer Center Hospital,³Kyoto University,⁴Cancer Institute Hospital of the Japanese Foundation for Cancer Research,⁵Kansai Electric Power Hospital,⁶Dokkyo Medical University,⁷Fukuoka Sanno Hospital,⁸Tohoku University School of Medicine,⁹Otsu Red Cross Hospital) : Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts. Pancreatology. 20(5). 944-950. 2020.
Sangro B¹, Melero I², Wadhawan S³, Finn RS⁴, Abou-Alfa GK⁵, Cheng AL⁶, Yau T⁷, Furuse J, Park JW⁸, Boyd Z³, Tang HT³, Shen Y³, Tschaika M³, Neely J³, El-Khoueiry A⁹ (¹Clinica Universidad de Navarra-IDISNA and CIBEREHD, ²Universidad de Navarra and CIBERONC,³Bristol Myers Squibb,⁴University of California, ⁵Memorial Sloan Kettering Cancer Center ,Weill Medical College at Cornell University ⁶National Taiwan University Hospital,⁷University of Hong Kong, ⁸National Cancer Center, 9USC Norris Comprehensive Cancer Center) : Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 73(6).1460-1469. 2020.
Shimoyama R¹, Hijioka S¹, Mizuno N², Ogawa G¹, Kataoka T¹, Katayama H¹, Machida N³, Honma Y¹, Boku N¹, Hamaguchi T⁴, Fukuda H¹, Terashima M³, Kanemitsu Y¹, Furuse J (¹National Cancer Center Hospital, ²Aichi Cancer Center Hospital,³Shizuoka Cancer Center,⁴Saitama Medical University International Medical Center) : Stomach Cancer Study Group/Colorectal Cancer Study Group/Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group. Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study). Pancreatology. 20(6). 1183-1188. 2020.
Matsuki R¹, Kawai K, Suzuki Y¹, Kogure M¹, Nakazato T¹, Naruge D, Okano N, Seki S¹, Ohmori Y¹, Kawamura N¹, Kamma H¹, Hisamatsu T¹, Shibahara J¹, Mori T¹, Furuse J, Sakamoto Y¹ (¹Kyorin University Hospital ): Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma. Liver Cancer. 9(3). 358-360.2020.
Kudo M¹, Okusaka T², Motomura K³, Ohno I⁴, Morimoto M⁵, Seo S⁶, Wada Y⁷, Sato S⁸, Yamashita T⁹, Furukawa M¹⁰, Aramaki T¹¹, Nadano S¹², Ohkawa K¹³, Fujii H¹⁴, Kudo T¹⁵, Furuse J, Takai H¹⁶, Homma G¹⁶, Yoshikawa R¹⁶, Zhu AX¹⁷ (¹Kindai University Faculty of Medicine, ²National Cancer Center Hospital,³Aso Iizuka Hospital,⁴National Cancer Center Hospital East, ⁵Kanagawa Cancer Center,⁶Kyoto University, 7Kyushu Medical Center,⁸Kyoundo Hospital,⁹Kanazawa University,¹⁰National Hospital Organization Kyushu Cancer Center,¹¹Shizuoka Cancer Center Hospital,¹²National Hospital Organization Shikoku Cancer Center,¹³Osaka International Cancer Institute,¹⁴Jichi Medical University,¹⁵Osaka University,¹⁶Eli Lilly Japan K.K,¹⁷Massachusetts General Hospital Cancer Center, Harvard Medical School) : Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J Gastroenterol. 55(6). 627-639. 2020.
Yamamoto N¹, Ryoo BY², Keam B³, Kudo M⁴, Lin CC⁵, Kunieda F⁶, Ball HA⁶, Moran D⁶, Komatsu K⁷, Takeda K⁶, Fukuda M⁷, Furuse J, Morita S⁸, Doi T⁹ (¹National Cancer Center Hospital,²Asan Medical Center, University of Ulsan,³Seoul National University Hospital,⁴Kindai University,⁵National Taiwan University Hospital,⁶Astellas Pharma Global Development,⁷Astellas Pharma,⁸Kyoto University, ⁹National Cancer Center Hospital East) : A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. Invest New Drugs.38(2). 445-456. 2020.
Okusaka T¹, Furuse J(¹National Cancer Center Hospital) : Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 55(4). 369-382. 2020.
U0eno M¹, Ikeda M², Sasaki T³, Nagashima F, Mizuno N⁴, Shimizu S⁵ , Ikezawa H⁶, Hayata N⁷, Nakajima R⁸, Morizane C⁹ (¹Kanagawa Cancer Centre Hospital,²National Cancer Center Hospital East,³Cancer Institute Hospital of JFCR,⁴Aichi Cancer Centre Hospital,⁵Saitama Cancer Centre,⁶Eisai Co. Ltd,⁷Eisai Inc,⁸National Cancer Centre Hospital) : Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer. 20(1). 1105. 2020.
Kobayashi N¹, Omae K², Horita Y³, Ueno H⁴, Mizuno N⁵, Uesugi K⁶, Sudo K⁷, Ozaka M⁸, Hayashi H⁹, Okano N, Kamei K¹⁰, Yamaguchi A¹¹, Kobayashi S¹², Suzuki S¹³, Ishihara S¹⁴, Uchiyama T¹⁵, Todaka A¹⁶, Fukutomi A¹⁶ (¹Yokohama City University Hospital,²Shizuoka Cancer Center,³Toyama Prefectural Central Hospital,⁴National Cancer Center Hospital,⁵Aichi Cancer Center, ⁶National Hospital Organization Shikoku Cancer Center,⁷Chiba Cancer Center,⁸Cancer Institute Hospital of Japanese Foundation for Cancer Research,⁹Hokkaido University Graduate School of Medicine,¹⁰Kindai University Hospital,¹¹Kure Medical Center and Chugoku Cancer Center,¹²Kanagawa Cancer Center,¹³Yamagata University Faculty of Medicine,¹⁴Fujita Health University,¹⁵Kikugawa General Hospital,¹⁶Shizuoka Cancer Center) : FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Pancreatology.20(7). 1519-1525. 2020.
Imaoka H¹, Ikeda M¹, Maehara K², Umemoto K³, Ozaka M⁴, Kobayashi S⁵, Terashima T⁶, Inoue H⁷, Sakaguchi C⁸, Tsuji K⁹, Shioji K¹⁰, Okamura K¹¹, Tsujimoto A¹², Nakamura I¹³, Shirakawa H¹⁴, Furukawa M¹⁵, Ueno M³, Morizane C², Furuse J (¹National Cancer Center Hospital East,²National Cancer Center Hospital,³St. Marianna University School of Medicine,⁴Cancer Institute Hospital Japanese Foundation for Cancer Research,⁵Kanagawa Cancer Center,⁶Kanazawa University Hospital,⁷Shizuoka Cancer Center,⁸Shikoku Cancer Center,⁹Ishikawa Prefectural Central Hospital,¹⁰Niigata Cancer Center Hospital,¹¹JA Sapporo Kohsei Hospital,¹²Chiba Cancer Center,¹³Hyogo College of Medicine,¹⁴Tochigi Cancer Center,¹⁵National Hospital Organization Kyushu Cancer Center) : Risk stratification and prognostic factors in patients with unresectable undifferentiated carcinoma of the pancreas. Pancreatology. 2021. DOI: 10.1016/j.pan.2021.02.008. [Epub]
Takai E¹, Nakamura H², Chiku S³, Kubo E⁴, Ohmoto A⁴, Totoki Y², Shibata T², Higuchi R⁵, Yamamoto M⁵, Furuse J, Shimizu K⁵, Takahashi H⁶, Morizane C⁴, Furukawa T⁷, Yachida S¹ (^1Osaka University,²National Cancer Center Research Institute,³Mizuho Information and Research Institute,⁴National Cancer Center Hospital,⁵Tokyo Women’s Medical University,⁶National Cancer Center Hospital East,⁷Tohoku University Graduate School of Medicine) : Whole-exome sequencing reveals new potential susceptibility genes for Japanese familial pancreatic cancer. Ann Surg. 2020. DOI : 10.1097/SLA.0000000000004213. Online ahead of print.
Maruki Y,¹ Morizane C¹, Arai Y², Ikeda M³, Ueno M⁴, Ioka T⁵, Naganuma A⁶, Furukawa M⁷, Mizuno N⁸, Uwagawa T⁹, Takahara N¹⁰, Kanai M¹¹, Asagi A¹², Shimizu S¹³, Miyamoto A¹⁴, Yukisawa S¹⁵, Kadokura M¹⁶, Kojima Y¹⁷, Furuse J, Nakajima TE^18,19, Sudo K²⁰, Kobayashi N²¹, Hama N²², Yamanaka T²³, Shibata T²⁴, Okusaka T¹ (¹National Cancer Center Hospital, ²National Cancer Center Research Institute,³National Cancer Center Hospital East,⁴Kanagawa Cancer Center,⁵Yamaguchi University Hospital,⁶National Hospital Organization Takasaki General Medical Center,⁷National Hospital Organization Kyushu Cancer Center,⁸Aichi Cancer Center Hospital, ⁹The Jikei University School of Medicine,¹⁰The University of Tokyo,¹¹Kyoto University,¹²National Hospital Organization Shikoku Cancer Center,¹³Saitama Cancer Center,¹⁴National Hospital Organization Osaka National Hospital,¹⁵Tochigi Cancer Center,¹⁶Kofu Municipal Hospital,¹⁷National Center for Global Health and Medicine,¹⁸St.Marianna University School of Medicine,¹⁹Kyoto University Hospital,²⁰Chiba Cancer Center,²¹Yokohama City University School of Medicine, ²²Yokohama City University Graduate School of Medicine) : Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study). J Gastroenterol. 56(3). 297. 2021.
Ueno M¹, Morizane C², Furukawa M³, Sakai D⁴, Komatsu Y⁵, Nakai Y⁶, Tsuda M⁷, Ozaka M⁸, Mizuno N⁹, Muto M¹⁰, Fukutomi A¹¹, Ikeda M¹², Tsuji A¹³, Katanuma A¹⁴, Moriwaki T¹⁵, Kajiwara T¹⁶, Ishii H¹⁷, Negoro Y¹⁸, Shimizu S¹⁹, Nemoto N²⁰, Kobayashi S²⁰, Makino K²⁰, Furuse J (¹Kanagawa Cancer Center,²National Cancer Center Hospital,³National Hospital Organization Kyushu Cancer Center,⁴Osaka University Graduate School of Medicine,⁵Hokkaido University Hospital,⁶The University of Tokyo,⁷Hyogo Cancer Center,⁸Cancer Institute Hospital of the Japanese Foundation for Cancer Research,⁹Aichi Cancer Center Hospital,¹⁰Kyoto University Hospital,¹¹Shizuoka Cancer Center,¹²National Cancer Center Hospital East,¹³Kagawa University,¹⁴Teine-keijinkai hospital,¹⁵University of Tsukuba,¹⁶National Hospital Organization Shikoku Cancer Center,¹⁷Chiba Cancer Center,¹⁸Kochi Health Sciences Center,¹⁹Saitama Cancer Center,²⁰Yakult Honsha Co.)：A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy. Cancer Med. 10(6). 2088-2099. 2021.
Yokokawa A¹, Kaneko S¹, Endo S¹, Minowa Y¹, Ayukawa H¹, Hirano R¹, Nagashima F, Naruge D, Okano N, Kobayashi T, Kawai K, Furuse J, Furuta T¹, Shibasaki H¹ (¹Tokyo University of Pharmacy and Life Sciences) : Effect of UGT1A¹, CYP3A and CES activities on the pharmacokinetics of irinotecan and its metabolites in patients with UGT1A1 gene polymorphisms. Eur J Drug Metab Pharmacokinet. 46(2). 317-324. 2021.
Umemoto K^1,2, Takahashi H¹, Morizane C¹, Yamada I³, Shimizu S⁴, Shioji K⁵, Yoshida Y⁶, Motoya M⁷, Mizuno N⁸, Kojima Y⁹, Terashima T¹⁰, Uesugi K¹¹, Ueno M¹², Furuse J, Akimoto T^1,2, Ikeda M¹(¹National Cancer Center Hospital East,²Juntendo University Graduate School of Medicine,³Cancer Institute Hospital, Japanese Foundation For Cancer Research,⁴Saitama Cancer Center,⁵Niigata Cancer Center Hospital,⁶Shizuoka Cancer Center,⁷Sapporo Medical University,⁸Aichi Cancer Center Hospital,⁹National Center for Global Health and Medicine,¹⁰Kanazawa University Hospital,¹¹National Hospital Organization Shikoku Cancer Center,¹²Kanagawa Cancer Center) : FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Cancer Chemother Pharmacol. 87(3). 397-404. 2021.
Ioka T^1,2, Furuse J, Fukutomi A³, Mizusawa J⁴, Nakamura S⁵, Hiraoka N⁴, Ito Y⁴, Katayama H⁴, Ueno M⁶, Ikeda M⁷, Sugimori K⁸, Okano N, Shimizu K⁹, Yanagimoto H¹⁰, Okusaka T⁴, Ozaka M¹¹, Todaka A⁴, Nakamori S¹², Tobimatsu K¹³, Sata N¹⁴, Kawashima Y¹⁵, Hosokawa A¹⁶, Yamaguchi T¹⁷, Miyakawa H¹⁸, Hara H¹⁹, Mizuno N²⁰, Ishii H¹⁷, Hepatobiliary and Pancreatic Oncology Group (HBPOG) of Japan Clinical Oncology Group (JCOG)(1Osaka International Cancer Institute, ²Yamaguchi University Hospital, ³Shizuoka Cancer Center,⁴National Cancer Center Hospital, 5Kansai Medical University Hospital, 6Kanagawa Cancer Center, 7National Cancer Center Hospital East, 8Yokohama City University Medical Center, 9Tokyo Women’s Medical University, 10Kansai Medical University, ¹¹Cancer Institute Hospital,¹²Osaka National Hospital,¹³Kobe University Graduate School of Medicine,¹⁴Jichi Medical University School of Medicine,¹⁵Tokai University School of Medicine,16University of Toyama,¹⁷Chiba Cancer Center,¹⁸Sapporo Kosei General Hospital,¹⁹Saitama Cancer Center,²⁰Aichi Cancer Center Hospital ) : Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. Jpn J Clin Oncol. 51(2). 235-243. 2021.
Kudo M¹, Tsuchiya K², Kato N³, Hagihara A⁴, Numata K⁵, Aikata H⁶, Inaba Y⁷, Kondo S⁸, Motomura K⁹, Furuse J, Ikeda M¹⁰, Morimoto M¹¹, Achira M¹², Kuroda S¹³, Kimura A¹⁴ (¹Kindai University ,²Musashino Red Cross Hospital ,³Chiba University , ⁴Osaka City University ,⁵Yokohama City University Medical Center,⁶Hiroshima University,⁷Aichi Cancer Center Hospital,⁸National Cancer Center Hospital ,⁹IIZUKA HOSPITAL,¹¹National Cancer Center Hospital East,¹²Kanagawa Cancer Center ,¹³PRA Development Center KK ,¹⁴Takeda Pharmaceutical Company Limited ) : Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. J Gastroenterol. J Gastroenterol. 56(2). 181-190. 2021.
Ueno M¹, Morinaga S¹, Hashimoto Y², Umemoto K², Sasahira N³, Saiur A³, Seyama Y⁴, Honda G⁵, Ioka T⁶, Takahashi H⁷, Miyamoto A⁸, Nakamori S⁸, Unno M⁹, Takadate T⁹, Mizuno N¹⁰, Shimizu Y¹⁰, Ueno H¹¹, Sugiyama M¹², Fukutomi A¹³, Shimizu S¹⁴, Okusaka T¹¹, Furuse J (¹Kanagawa Cancer Center,²National Cancer Center Hospital East,³Cancer Institute Hospital of Japanese Foundation for Cancer Research,⁴Bokuto Hospital,⁵Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, ⁶Yamaguchi University,⁷Osaka International Cancer Institute, ⁸National Hospital Organization Osaka National Hospital,⁹Tohoku University Graduate School of Medicine,¹⁰Aichi Cancer Center Hospital,¹¹National Cancer Center Hospital,¹²Department of Surgery, Kyorin University,¹³Shizuoka Cancer Center,¹⁴Saitama Cancer Center) : Tolerability of nab-paclitaxel plus gemcitabine as adjuvant setting in Japanese patients with resected pancreatic cancer: phase I study. Pancreas.50(1).83-88. 2021.
Nagino M¹, Hirano S², Yoshitomi H³, Aoki T³, Uesaka K⁴, Unno M⁵, Ebata T⁶, Konishi M⁷, Sano K⁸, Shimada K⁹, Shimizu H¹⁰, Higuchi R¹¹, Wakai T¹², Isayama H¹³, Okusaka T⁹, Tsuyuguchi T¹⁴, Hirooka Y¹⁵, Furuse J, Maguchi H¹⁶, Suzuki K¹⁷, Yamazaki H¹⁸, Kijima H¹⁹, Yanagisawa A²⁰, Yoshida M²¹,Yokoyama Y⁶, Mizuno T⁶, Endo I²² (¹Aichi Cancer Center,²Hokkaido University,³Dokkyo Medical University,⁴Shizuoka Cancer Center,⁵Tohoku University Graduate School of Medicine,⁶Nagoya University Graduate School of Medicine,⁷National Cancer Center Hospital East,⁸Teikyo University School of Medicine,⁹Tokyo National Cancer Center Hospital,¹⁰Teikyo University Chiba Medical Center,¹¹Tokyo Women’s Medical University,¹²Niigata University Graduate School of Medical and Dental Sciences,¹³Juntendo University,¹⁴Chiba Prefectural Sawara Hospital,¹⁵ Fujita Health University,¹⁶Teine-Keijinkai Hospital,¹⁷Aichi Medical University,¹⁸Kyoto Prefectural University of Medicine,¹⁹Hirosaki University Graduate School of Medicine, ²⁰Japanese Red Cross Kyoto Diichi Hospital,²¹International University of Health and Welfare,²²Yokohama City University) : Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition . J Hepatobiliary Pancreat Sci. 28(1). 26-54. 2021.
Yamamoto M¹, Yoshida M², Furuse J, Sano K³, Ohtsuka M⁴, Yamashita S¹, Beppu T⁵, Iwashita Y⁶, Wada K³, Nakajima TE^7.8, Sakamoto K⁹, Hayano K¹⁰, Mori Y¹¹, Asai K¹², Matsuyama R¹³, Hirashita T¹, Hibi T¹⁴, Sakai N⁴, Tabata T¹⁵, Kawakami H¹⁶, Takeda H⁷, Mizukami T⁷, Ozaka M¹⁷, Ueno M¹⁸, Naito Y¹⁹, Okano N, Ueno T²⁰, Hijioka S²¹, Shikata S²², Ukai T²³, Strasberg S²⁴ , Sarr MG²⁵, Jagannath P²⁶, Hwang TL²⁷, Han HS²⁸, Yoon YS²⁸, Wang HJ²⁹, Luo SC³⁰, Adam R³¹ , Gimenez M^32,33, Scatton O³⁴, Oh DY³⁵, Takada T³ (¹Tokyo Women’s Medical University,²International University of Health and Welfare,³Teikyo University School of Medicine,⁴Chiba University,⁵Yamaga City Medical Center,⁶Oita University Faculty of Medicine,⁷St. Marianna University School of Medicine,⁸Kyoto University Hospital,⁹Ehime University Graduate School of Medicine,¹⁰Chiba University,¹¹Kyushu University,¹²Toho University Ohashi Medical Center,¹³Yokohama City University Graduate School of Medicine,¹⁴Kumamoto University Graduate School of Medical Sciences,¹⁵Kindai University Faculty of Medicine,¹⁶Cancer Institute Hospital of the Japanese Foundation for Cancer Research,¹⁷Kanagawa Cancer Center,¹⁸National Cancer Center Hospital East,¹⁹Cancer Institute Hospital, ²⁰National Cancer Center Hospital,²¹Mie Prefectural Ichishi Hospital,²²Osaka Institute of Public Health,²³Washington University in St. Louis,²⁴Mayo Clinic, ²⁵Lilavati Hospital & SL Raheja Hospital,²⁶Chang Gung Memorial Hospital at Linkou, Chang Gung University,²⁷Seoul National University Bundang Hospital, Seoul National University College of Medicine,²⁸Ajou University School of Medicine,²⁹Taichung Veterans General Hospital,³⁰AP HP Paul Brousse Hospital, University Paris Sud,³¹University of Buenos Aires, ³²Institute of Image-Guided Surgery,³³APHP Pitié-Salpêtrière Hospital, Sorbonne Université,³⁴Seoul National University Hospital Cancer Research Institute,³⁵Seoul National University College of Medicine)：Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. J Hepatobiliary Pancreat Sci. 28(1).1-25. 2021.
Takahashi H¹, Ikeda M¹, Shiba S², Imaoka H³, Todaka A⁴, Shioji K⁵, Yane K⁶, Kojima Y⁷, Kobayashi S⁸, Asagi A⁹, Ozaka M¹⁰, Takada R¹¹, Nagashio Y¹², Horiguchi S¹³, Kasuga A¹⁴, Suzuki E¹⁵, Terashima T¹⁶, Ueno M⁸, Morizane C², Furuse J（¹National Cancer Center Hospital East,²National Cancer Center Hospital,³Aichi Cancer Center Hospital,⁴Shizuoka Cancer Center,⁵Niigata Cancer Center Hospital,⁶Teine-Keijinkai Hospital,⁷National Center for Global Health and Medicine,⁸Kanagawa Cancer Center, ⁹National Hospital Organization Shikoku Cancer Center,¹⁰Cancer Institute Hospital of Japanese Foundation for Cancer Research,¹¹Osaka International Cancer Institute,¹²National Kyushu Cancer Center,¹³Okayama University Graduate School of Medicine,¹⁴Cancer Institute Hospital of the Japanese Foundation for Cancer Research,¹⁵Chiba University,¹⁶Kanazawa University Hospital）: Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell carcinoma: potential efficacy of platinum- and irinotecan-containing regimens. Pancreas. 50(1). 77-82. 2021.
Inomata K¹, Yokoi H¹ ,Fujiwara M¹, Kimura Y², Matsumoto Y¹, Naito S¹, Ohara A³, Okano N, Kanmma H², Saito K¹(^{¹Department of Otolaryngology-Head and Neck Surgery, Kyorin University School of Medicine,²Department of Pathology , Kyorin University School of Medicine,³Department of Radiology, Kyorin University School of Medicine) : Case of thyroid transcription factor-1-positive neuroendocrine carcinoma of the sphenoid sinus with bone　metastases. Human Pathology. Case Reports.24. 2021. https://doi.org/10.1016/j.ehpc.2021.200492.}
Tsubata Y¹, Shinomiya S², Inoue K³, Ishikawa N⁴, Saito R⁵, Nakashima K¹, Hotta K⁶, Hamada A⁷, Nagashima F, Ando Y⁸, Morita S⁹, Kobayashi K², Isobe T⁶ (¹Shimane University Faculty of Medicine,²Saitama Medical University International Medical Center,³Ehime Prefectural Central Hospital,⁴Hiroshima Prefectural Hospital,⁵Tohoku University Hospital,⁶Okayama University Hospital,⁷National Cancer Center Research Institute,⁸Nagoya University Hospital,⁹Kyoto University Graduate School of Medicine) : Protocol for a multi-site, cluster-randomized, phase III, comparative clinical trial of geriatric assessment of older patients with non-small-cell lung cancer: the ENSURE-GA study. BMC Geriatr. 21(1). 74. 2021.

和文

古瀬純司 : 切除不能膵癌に対する臨床試験のup-to-date. 胆と膵. 42(1). 67-71. 2021.
古瀬純司 : 肝細胞がんに対する薬物療法の進歩. がん分子標的治療 18(2). 151-156. 2021.
岡野尚弘, 長島文夫, 古瀬純司：各臓器がんのゲノム診療の現状　消化器がん．腫瘍内科．27(1)．73-80．2021．
岡野尚弘，西岡真理子，杉浦ちとせ，前園知宏，河合桐男，小林敬明，水谷友紀，長島文夫，古瀬純司：進行膵癌の化学療法．進行胆道癌・膵癌の治療限界を打ち破る－症例から学ぶ究極の治療．胆と膵．41(5)．487-492．2020．
西岡真理子，長島文夫，古瀬純司：膵がん治療の最前線―化学療法―．膵炎・膵がん診療のUp To Date．臨牀と研究．97(5)．548-555．2020．
古瀬純司：肝細胞癌に対する治療薬の今後の展望．肝臓クリニカルアップデート 6(1)．85-90．2020.
古瀬純司：膵癌悪液質患者への栄養サポート－アナモレリンの特徴．胆と膵．41(7)．679-682．2020．
長島文夫，水谷友紀，岡野尚弘，西岡真理子，河合桐男，前園知宏，杉浦ちとせ，廣田玲，小林敬明，前野聡子，佐々木ヱリ，古瀬純司 : 高齢者のがん診療について．新薬と臨牀．69(8)．998-1003．2020．
前園知宏，古瀬純司：胆膵疾患治療の最前線パラダイムシフトも含めて切除不能膵癌に対する化学療法 . Medical Practice. 37(8). 1291-1296．2020．
古瀬純司：肝・胆道・膵癌におけるConversion surgeryの意義－腫瘍内科医の立場から．手術．74(10)．1413-1418．2020.
古瀬純司：免疫チェックポイント阻害剤同士の併用療法デュルバルマブ＋トレメリムマブ併用療法のupdate (Study 22)－肝細胞癌治療のパラダイムチェンジ－進化する薬物療法2020 Update Part1－（免疫療法）．肝胆膵．81(4)．713-717．2020．
岡野尚弘，長島文夫，古瀬純司：進行肝癌の1st line試験（RATIONALE-301, HIMARAYA, CM-9DW, LEAP-002,COSMIC-312）の概要．肝細胞癌治療のパラダイムチェンジ－進化する薬物療法2020 Update Part1－（免疫療法）．肝胆膵．81(4)．729-735．2020．
岡野尚弘，廣田玲，西岡真理子，杉浦ちとせ，前園知宏，河合桐男，水谷友紀，長島文夫，古瀬純司：胆道癌薬物療法の最新動向．臨床外科．75(13)．1484-1488．2020．
古瀬純司：肝細胞がんに対する薬物療法の進歩．がん分子標的治療．18(2)．151-156．2021.
古瀬純司：肝細胞がん薬物療法．THE GI FOREFRONT．16(2)．114-117．2020．
古瀬純司 : IPMNに対する化学療法：術後補助療法および切除不能例に対する化学療法レジメンの選択. 胆と膵. 41. 1351-1353. 2020.
松井敏史，須藤珠水，永田あかね，山中崇，木棚究，水木麻衣子，長島文夫，前野聡子，佐々木ヱリ，池村健，裵東海，武久敬洋：要介護高齢者のロボットリハビリテーション. 老年内科. 3(2). 191-204. 2020.
長島文夫，桶川隆嗣1 (1杏林大・医・泌尿器科学)：特集「ここまできたがん免疫療法」対談「がん免疫療法の現状と展望」. 杏林医学会雑誌. 51(4).279-282.2020.
岡野尚弘：大腸癌の術後補助療法-最適な使い分け-．消化器内科．3(3)．12-20．2021．

著　書

古瀬純司(総監修)：膵癌診療の動向-序文に代えて．日本膵臓学会50周年記念誌．膵臓病学臨床・研究の50年－日本膵臓学会と膵癌診療のあゆみ－．アークメデイア．2021．
小林智，石井浩，古瀬純司：薬物療法．膵癌．高齢者がん医療Q&A 臓器別編．日本がんサポーティブケア学会編集．金原出版．2020．144-154．
古瀬純司：膵疾患の治療・処置総論．抗癌薬治療．膵臓病診療ガイドブック．日本膵臓学会教育委員会編集．診断と治療社．2020．146-150．
古瀬純司：肝細胞癌に対するラムシルマブ2次治療の第Ⅲ相試験（REACH試験）の総括．ラムシルマブによる肝細胞がん治療．工藤正俊監修．アークメディア．2020．43-47．
古瀬純司（編集）:．消化器ナーシング　臓器別消化器がん化学療法・薬物療法．メディカ出版．2020．
岡野尚弘（分担執筆）：レゴラフェニブ．がん化学療法の薬はや調べノート．メディカ出版．2020．62-63.
岡野尚弘（分担執筆）：バンデタニブ．がん化学療法の薬はや調べノート．メディカ出版．2020．64-65．
岡野尚弘（分担執筆）：オラパリブ．がん化学療法の薬はや調べノート．メディカ出版．2020．150-151．
岡野尚弘（分担執筆）：ゲムシタビン．がん化学療法の薬はや調べノート．メディカ出版．2020．176-177．
岡野尚弘（分担執筆）：パクリタキセル．がん化学療法の薬はや調べノート．メディカ出版．2020．272-273．
岡野尚弘（分担執筆）：ナブパクリタキセル．がん化学療法の薬はや調べノート．メディカ出版．2020．274-275．
岡野尚弘（分担執筆）：ドセタキセル．がん化学療法の薬はや調べノート．メディカ出版．2020．276-277．
岡野尚弘（分担執筆）：胆道癌一次治療、二次治療．オンコロジークリニカルガイド　消化器癌化学療法改訂5版．室圭・大村健二編集．南山堂．2020．P288-293．

報告書

長島文夫：患者・家族の意思決定能力に応じた適切な意思決定支援の実践に資する簡便で効果的な支援プログラムの開発に関する研究．厚生労働科学研究費補助金(がん対策推進総合研究事業)2020年度　分担研究報告書．
長島文夫：高齢者がん診療指針策定に必要な基盤整備に関する研究．厚生労働科学研究費補助金 (がん対策推進総合研究事業)2020年度　分担研究報告書．

その他

【座長・司会・主催】

長島文夫：切除不能進行胃がん高齢患者の治療．GI Cancer Cutting Edge　Web座談会．オンライン．2020年8月20日.
長島文夫：老年腫瘍学セミナー. オンライン．2021年2月27日.
長島文夫：東日本大震災から10年災害に備えるまちづくりを考える．第9回杏林CCRCフォーラム．オンライン．2021年3月13日.

講　演

長島文夫：高齢者前立腺癌治療監視療法からCRPCまで高齢者における癌治療について本邦における老年腫瘍学．第107回日本泌尿器科学会総会，名古屋，2019年4月18日.
Furuse J: Up-To-Date systemic treatments for hepatocellular carcinoma. 8th International Forum of the Japanese Society of Gastroenterology. 第105回日本消化器病学会総会，金沢，2019年5月9日.
岡野尚弘，松木亮太，土岐真朗，立石秀勝，渡邉俊介，鈴木裕，柴原純二，阪本良弘，杉山政則，古瀬純司：Borderline resectable膵癌に対する術前治療としてのゲムシタビン+ナブパクリタキセル療法のfeasibility試験．第105回日本消化器病学会総会，金沢，2019年5月10日．
古瀬純司 : 最新の膵癌治療の動向－薬物療法の進歩．第22回湖南・東近江消化器カンファレンス，近江八幡，2019年5月16日．
古瀬純司：MSI-High膵癌・胆道癌における新たな治療戦略－免疫チェックポイント阻害剤登場. Oncologyインターネット講演会，東京，2019年5月23日．
Nara S, Shimada K, Uesaka K, Konish M, Ohtsuka M, Hirono S, Unno M, Yanagimoto H, Nomura T, Sata N, Wada H, Hatano E, Sakamoto H, Ohta T, Fujino Y, Morinaga S, Tahara M, Ambo Y, Ohta K, Fujii T, Shirakawa H, Nagano H, Miyamoto A, Takeda K, Sugimachi K, Furuse J : The assessment of preoperative diagnostic accuracy of multidetector-row computed tomography (MDCT) for resectable biliary tract cancer- multi-institutional validity study in Japan. Digestive Disease Week 2019, USA, May 18th-21st, 2019.
Shibasaki-Hirano H, Usukura C, Katsumata S, Hirahara Y, Hirano R, Yokokawa A, Maesono T, Kawai K, Nishioka M, Kobayashi T, Okano N, Nagashima F, Furuse J : Simultaneous measurement of regorafenib and its metabolites in human plasma using HPLC and pharmacokinetics in Japanese patients. 日本TDM学会学術集会，東京，2019年5月25-26日．
Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J: First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: results from a phase 1b trial (VEGF Liver 100). ASCO2019, USA, June 3rd, 2019.
古瀬純司 : 肝細胞癌に対する薬物療法：最近の話題と今後の展望．第31回日本肝胆膵外科学会学術集会，高松，2019年6月14日．
Furuse J, Kawakami H, Mizukami T, Ozaka M, Okano N, Ueno M, Hijioka S, Ueno T, Naito Y, Nakajima TE: International clinical practice guidelines for metastatic liver tumors: Interim report. The 31st Meeting of Japan Society of Hepato-Biliary-Pancreatic Surgery, 高松，2019年6月14日．
長島文夫：高齢者がん診療の考え方　高齢者機能評価と意思決定支援を含めて．第1回地域がん医療連携研修会，横浜，2019年6月25日．
池田公史，工藤正俊，奥坂拓志，本村健太，大野泉，森本学，瀬尾智，和田幸之，佐藤新平，山下竜也，古川正幸，新槇剛，灘野成人，大川和良，藤井博文，工藤敏啓，古瀬純司，髙井弘基，本間剛介，吉川麗月，Andrew X. Zhu：ソラフェニブ後のAFP高値進行肝細胞癌に対するラムシルマブ：2つの国際共同無作為化第3相試験の併合解析における日本人患者の有効性と安全性．第20回日本肝がん分子標的治療研究会，長崎，2019年6月29日．
古瀬純司，泉並木，工藤正俊，本村健太，薮下和久，稲葉吉隆，片村嘉男，近藤泰輝：切除不能な肝細胞癌患者に対するレンバチニブ投与の多施設観察研究-中間報告-．第20回日本肝がん分子標的治療研究会，長崎，2019年6月29日．
古瀬純司 : バイオマーカー．（特別発言）第55回日本肝癌研究会，東京，2019年7月5日.
古瀬純司 : 膵癌の薬物療法-これまでとこれから．第50回日本膵臓学会大会，東京，2019年7月12-13日.
古瀬純司，福冨晃，水野伸匡，尾阪将人，井岡達也，奥坂拓志 : 切除不能膵癌に対する化学療法．膵癌診療ガイドライン2019．膵癌診療の進歩値明日への提言．第50回日本膵臓学会大会，東京，2019年7月12-13日．
庄司広和，工藤千恵，高石官均，高橋直樹，傳田忠道，川上武志，山口研成，古瀬純司，森脇俊和，高野利美，澤田亮一，宮本敬大，今関洋，青木一教，室圭，朴成和：標準治療に不応不耐進行胃癌患者に対するNivoluamb療法のBiomarker研究．第17回日本臨床腫瘍学会学術集会，京都，2019年7月18日．
津村英隆，森実千種，野村尚吾，高橋秀明，岡野尚弘，水野伸匡，佐竹悠良，辻国広，塩路和彦，浅木彰則，安居幸一郎，宮川浩之，石黒敦，小倉孝，上野誠，飛松和俊，寺島健志，池田公史，奥坂拓志，古瀬純司：Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer. 第17回日本臨床腫瘍学会学術集会，京都，2019年7月19日.
Morizane C, Ikeda M, Ueno M, Kobayashi S, Ohno I, Kondo S, Okano N, Kimura K, Asada S, Namba Y, Okusaka T, Furuse J: Open-label, phase I study of nivolumab or nivolumab/cisplatin/gemcitabine in patients with unresectable/recurrent biliary tract cancer. 第17回日本臨床腫瘍学会学術集会，京都，2019年7月19日.
Ikeda M, Okuyama H, Okusaka T, Furuse J, Furukawa M, Ohkawa S, Hosokawa A, Kojima Y, Hara H, Murohisa G, Shioji K, Asagi A, Mizuno N, Kojima M, Yamanaka T: Everolimus for advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based chemotherapy. 第17回日本臨床腫瘍学会学術集会，京都，2019年7月19日．
岡野尚弘：好中球減少に対するマネジメント．第17回日本臨床腫瘍学会学術集会，京都，2019年7月19日.
古瀬純司，丸山大，木村綾，中村健一，福田治彦 : JCOGにおける患者参画の取り組みと展望．臨床試験への患者参画．第17回日本臨床腫瘍学会学術集会，京都，2019年7月20日．
古瀬純司 : 肝細胞癌の治療戦略-薬物療法の動向と今後の展望．第2回Digestive Expert Forum in Osaka，大阪，2019年7月26日．
長島文夫：高齢者のがん診療の考え方．第28回多摩骨軟部腫瘍研究会，三鷹，2019年8月24日．
Furuse J: Molecular targeted therapy for advanced HCC: review of the clinical trials results. Molecular Targeted Therapy: Regional Difference of Treatment Strategy for Intermediate/Advanced stage HCC Patients in a Era of Multi-Targeted Agents Era. The 10th Asia-Pacific Primary Liver Cancer Expert Meeting. 札幌，2019年8月31日．
古瀬純司：肝細胞癌の薬物療法ー1次治療から2次治療へのエビデンス．NEXT Web conference，東京，2019年9月4日．
古瀬純司：肝細胞癌の治療戦略-薬物療法の動向と今後の展望．第15回広島肝胆膵研究会，広島，2019年9月6日.
佐々木ヱリ，前野聡子，河合桐男，小林敬明，岡野尚弘，北村浩，古瀬純司，長島文夫：がん従事者に対するロボット介護機器のアンケ―ト調査．第4回日本がんサポーティブケア学会学術集会，青森，2019年9月6‐7日．
前野聡子，佐々木ヱリ，河合桐男，小林敬明，岡野尚弘，北村浩，古瀬純司，長島文夫：高齢がん患者における脆弱性の評価と介入を行った症例～各種ガイドラインの活用．第4回日本がんサポーティブケア学会学術集会，青森，2019年9月6‐7日．
佐々木哲哉，前野聡子，佐々木ヱリ，長島文夫：殺細胞性抗癌薬の添付文書に掲載される依存症治療薬との薬物間相互作用の評価．第4回日本がんサポーティブケア学会学術集会，青森，2019年9月6‐7日．
古瀬純司：膵癌化学療法の進歩と期待．第164回福岡膵懇話会学術講演会，福岡，2019年9月11日．
長島文夫：高齢者のがん薬物治療の考え方．東京都病院薬剤師会臨床薬学研究会，八王子，2019年9月19日．
古瀬純司：膵がん薬物療法の進歩－がんゲノム医療でどう変わる？．第71回日本消化器画像診断研究会，和歌山，2019年9月21日．
Okano N, Ueno M, Morizane C, Yamanaka T, Ojima H, Ozaka M, Sasaki M, Takahara N, Kobayashi S, Morimoto M, Hosoi H, Nakai Y, Ikeda M, Maeno S, Nagashima F, Okusaka T, Furuse J : Multicenter phase II trial　of　axitinib　monotherapy　for　advanced　biliary　tract　cancer　refractory　to　gemcitabine-based chemotherapy. ESMO2019, Spain, September 27th-October 1st, 2019.
Hashimoto Y, Hijioka S, Hirooka Y, Ohno E, Ioka T, Kobahashi S, Okusaka T, Maruki Y, Yashika J, Ashida R, Furuse J, Ikeda M, Kasuya H, Tanaka M, Ueno M : Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer. ESMO2019, Spain, September 27th-October 1st, 2019.
Hijioka S, Ueno M, Ioka T, Hirooka Y, Ohno E, Ozaka M, Okusaka T, Maruki Y, Kobahashi S, Ashida R, Yashika J, Furuse J, Ikeda M, Kasuya H, Tanaka M, Hashimoto Y: Phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer. ESMO2019, Spain, September 27th-October 1st, 2019.
Okamoto W, Nakamura Y, Shiozawa M, Komatsu Y, Denda T, Hara H, Kagawa Y, Narita Y，Kawakami H, Esaki T, Nishina T, Izawa N, Ando K, Moriwaki T, Kato T, Nagashima F, Satoh T, Nomura S, Yoshino T，Akagi K：Microsatellite Instability Status in Metastatic Colorectal Cancer and Effect of Immune Checkpoint Inhibitors on Survival in MSI-High Metastatic Colorectal Cancer. ESMO 2019，Spain，September 27th- October 1st，2019．
Kawamoto Y, Nakamura Y, Ikeda M, Bando H, Esaki T, Ueno M, Nishino T, Kagawa Y. Oki E, Denta T, Mizukami T, Tkahashi N, Okano N, Miki I, Sakamoto Y, M.Lefterova, J.Odegaard, Taniguchi H, Morizane C, Yoshino T : Biological difference of tumor mutational burden(TMB)and microsatellite instability(MSI)status in patients with somatic vs. germline BRCA1/2-mutated advanced gastrointestinal(GI)cancers using cell-free DNA(cfDNA)sequencing analysis in the GOZILA study. ESMO 2019，Spain，September 27th- October 1st，2019．
古瀬純司，奥坂拓志，小西大，山崎秀哉：胆道癌診療ガイドライン改訂のポイント：胆道癌に対する化学療法・放射線療法．第55回日本胆道学会学術集会，名古屋，2019年10月3-4日．
長島文夫：高齢者のがん医療の考え方．Nagasaki Hematology Seminar，長崎，2019年10月4日.
長島文夫：高齢者のがん診療の考え方：第多摩エリアの化学療法を考える会．調布，2019年10月11日．
Nakajima TE, Mizukami T, Takeda H, Kawakami H, Okano N, Ueno M, Hijioka S, Ozaka M, Ueno T, Naito Y, Furuse J: Chemotherapy. International clinical practice guidelines for metastatic liver tumors. 第57回日本癌治療学会学術集会，福岡，2019年10月24日．
長島文夫，岡野尚弘，河合桐男，前園知宏，西岡真理子，杉浦ちとせ，小林敬明，水谷友紀,古瀬純司：高齢者に対するがん治療の適応と限界：日本における老年腫瘍学の現状．第57回日本癌治療学会学術集会，福岡，2019年10月24日.
中島貴子，水上拓郎，武田弘幸，川上尚人，岡野尚弘，上野誠，肱岡範，尾坂将人，上野貴之，内藤陽一，古瀬純司：転移性肝腫瘍国際診療ガイドライン中間報告．第57回日本癌治療学会学術集会，福岡，2019年10月24日.
古瀬純司：がん腫別に考える体重減少とその要因：膵癌．第57回日本癌治療学会学術集会，福岡，2019年10月25日．
西岡真理子，古瀬純司：当院のゲムシタビン不応膵癌に対するゲムシタビン＋ナブパクリタキセル併用療法の治療成績．第57回日本癌治療学会学術集会，福岡，2019年10月25日.
Furuse J, Okano N, Ueno M, Kawai M, Yamanaka T, Yamaue H: Conversion Surgery for unresectable Pancreatic Cancer. 第57回日本癌治療学会学術集会，福岡，2019年10月26日.
河合桐男，古瀬純司 : 50%以上の肝占拠病変もしくは門脈本幹浸潤Vp4の肝細胞癌にレンバチニを使用した3例．第57回日本癌治療学会学術集会，福岡，2019年10月26日．
前園知宏，古瀬純司：切除可能膵癌への術後補助療法S-1後に再発した切除不能膵癌へのFOLFIRINOX療法の検討．第57回日本癌治療学会学術集会，福岡，2019年10月26日．
長島文夫：高齢者がん診療の考え方―国内外のガイドラインを参考に―．第15回GI-Net Club学術講演会，大阪，2019年10月26日．
長島文夫：高齢者のがん薬物療法の考え方―国内外のガイドラインを参考に―．第4回栃木県がん領域薬剤師フォーラム，宇都宮，2019年10月28日．
長島文夫：高齢者のがん治療．杏林大学公開講演会，三鷹，2019年11月2日．
Hiraoka Y, Nakamura Y, Kawamoto Y, Ikeda M, Bando H, Esaki T, Ueno M, Nishina T, Kagawa Y, Oki E, Denda T, Migita O, Takahashi N, Okano N, Ogata Y, Lefterova M, Odegaaed J, Taniguchi H, Morizane C, Yoshino T, Kuwata T: Purative Germline BRCA1/2 Mutations in Patients(pts)with Advanced Gastrointestinal(GI)Cancers Using Circulating Cell-Free Tumor DNA(cfDNA) Analysis in the GOZAILA study. NSGC38th Annual Conference, USA, November 5th-8th, 2019.
Maesono T, Nishioka M, Sugiura C, Kawai K.Okano N, Kobayashi T, Mizutani T, Nagashima F, Shibahara J, Sakamoto Y, Furuse J: A Case of Unresectable Pancreatic Cancer with BRCA1 Gene Mutation Effectively Worked by modified FOLFIRINOX after Gemcitabine plus nab-Paclitaxel Refractory. APA-JPS joint meeting in 2019, USA, November 7th, 2019.
Matsuoka A, Tsubata Y, Mizutani T, Takahashi M, Shimodaira H, Hamamoto Y, Nagashima F, Ando Y：Development and Distribution of the Japanese Edition of SIOG Educational Materials, 19th Conference of the international Society of Geriatric Oncology, Switzerland, November 14th-16th, 2019.
黒澤貴志，岡野尚弘，松木亮太，西岡真理子，前園知宏，河合桐男，小林敬明，鈴木裕，長島文夫，柴原純二，阪本良弘，古瀬純司：切除不能膵癌に対するconversion surgery後の再発と治療選択について．JDDW2019，第61回日本消化器病学会大会，神戸，2019年11月21日.
古瀬純司：肝細胞がんにおける薬物療法－最近の動向．JDDW2019，第23回日本肝臓学会大会，神戸，2019年11月22日．
岡野尚弘：胆膵癌化学療法最新の知見．第27回日本消化器関連学会週間，神戸，2019年11月23日.
古瀬純司：がんゲノム医療の現状と動向ー今何ができるか．多摩エリア大腸がんeセミナー，立川，2019年11月28日．
坂田好美，古瀬純司：VTE Expert meeting in MITAKA，三鷹，2019年11月29日．
Ioka T, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, Furukawa M, Okusaka T, Kawabe K, Furuse J, Komatsu Y, Ishii H, Sato A, Shimizu S, Chugh P, Rui Tang R, Seraj J, Ueno M: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC). ESMO-Asia 2019, Singpore, November 22nd-24th, 2019.
古瀬純司：膵・胆道癌薬物療法の最近の動向とJCOG肝胆膵グループの取り組み．第7回関西肝胆道オンコロジーグループ学術集会，山口，2019年12月21日．
古瀬純司：膵がん治療の最前線－がんゲノム医療は膵がん治療を変える．パンキャンジャパン膵臓がん勉強会クリスマス・スペシャル，東京，2019年12月22日．
古瀬純司，吉岡祐亮：ゲノム医療の時代におけるリキッドバイオプシーの役割．第4回リキッドバイオプシー研究会，東京，2020年1月17-18日.
Nakamura Y, Taniguchi H, Bando H, Kato K, Esaki T, Komatsu Y, Takahashi N, Ueno M, Kagawa Y, Nishina T, Kato T, Yamamoto Y, Furuse J, Denda T, Kawakami H, Oki E, Sunakawa Y, Satoh T, Yoshino T, Ohtsu A: Utility of Circulating Tumor DNA (ctDNA) versus Tumor Tissue Clinical Sequencing for Enrolling Patients with Advanced Gastrointestinal (GI) Cancer to Matched Clinical Trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
Morizane C, Ueno M, Ioka T, Tajika M, Ikeda M, Yamaguchi K, Hara H, Yabusaki H, Miyamoto A, Iwasa S, Muto M, Takashima T, Minashi K, Komatsu Y, Nishina T, Nakajima TE, Sahara T, Funasaka S, Yashiro M, Furuse J: Expansion part of phase 1 study of E7090 in patients with cholangiocarcinoma harboring FGFR2 gene fusion and with gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expression. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
Yoshida Y, Fukutomi A, Ueno M, Mori K, Watanabe K, Ohba A, Kobayashi S, Furuta M, Tsujimoto A, Osaka M, Okano N, Yane K, Umemoto K, Kawamoto Y, Terashima T, Tsumura H, Doi K, Shioji K, Asagi A, Furuse J: Efficacy of chemotherapy for patients with unresectable or recurrent pancreatic adenosquamous carcinoma: a multicenter retrospective analysis. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
Todaka A, Nara S, Motoi F, Morinaga S, Hama N, Higuchi R, Konishi M, Shirakawa H, Tsumura H, Okuyama H, Matsui H, Shioji K, Sugimachi K, Asagi A, Mizuno N, Fukutomi A, Furuse J: Multicenter retrospective observational study of pancreatic cancer with positive peritoneal lavage cytology intended for surgical resection. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater JA, Wasan HS, Borad MJ, Lihou CF, Zhen H, Luis Féliz L, Asatiani E, Jiang P, Vogel A: FIGHT-302: Phase 3 Study of First-line Pemigatinib Versus Gemcitabine Plus Cisplatin for Cholangiocarcinoma With FGFR2 Fusions or Rearrangements. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
Borad MJ, Bridgewater JA, Morizane C, Shroff RT, Oh DY, Moehler M, Furuse J, Benhadji KA, He Y, Valle JW: An open-label, randomized phase 3 study of futibatinib (TAS-120) versus gemcitabine-cisplatin chemotherapy as first-line treatment for patients with advanced cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene rearrangements (FOENIX-CCA3). 2020 Gastrointestinal cancers symposium, January 23rd-25th, 2020.
古瀬純司：膵がん薬物療法の進歩－がんゲノム医療でどう変わる?．T-CORE college 2020, 仙台，2020年2月8日.
Furuse J: Patient and Public Involvement, PPI. JCOG-EORTC symposium, Tokyo, February 15th, 2020.
長島文夫：高齢がん患者の治療選択について考える. 第34回日本がん看護学会学術集会，東京，2020年2月22日.

論　文

欧文

Kudo M¹, Ueshima K¹, Ikeda M², Torimura T³, Tanabe N⁴, Aikata H⁵, Izumi N⁶, Yamasaki T⁷, Nojiri S⁸, Hino K⁹, Tsumura H¹⁰, Kuzuya T¹¹, Isoda N¹², Yasui K¹³, Aino H¹⁴, Ido A¹⁵, Kawabe N¹⁶, Nakao K¹⁷, Wada Y¹⁸, Yokosuka O¹⁹, Yoshimura K²⁰, Okusaka T²¹, Furuse J, Kokudo N²², Okita K²³, Johnson PJ²⁴, Arai Y²¹(¹Kindai University Faculty of Medicine, ²National Cancer Center Hospital East, ³Kurume University School of Medicine, ⁴National Hospital Organisation Sendai Medical Center, ⁵Hiroshima University, ⁶Musashino Red Cross Hospital, ⁷Yamaguchi University Graduate School of Medicine, ⁸Nagoya City University Graduate School of Medical Sciences, ⁹Kawasaki Medical School, ¹⁰Hyogo Cancer Center, ¹¹Nagoya University Graduate School of Medicine, ¹²Jichi Medical University, ¹³Kyoto Prefectural University of Medicine, ¹⁴Social Insurance Tagawa Hospital, ¹⁵Kagoshima University Graduate School of Medical and Dental Sciences, ¹⁶Fujita Health University School of Medicine, ¹⁷Nagasaki University Graduate School of Biomedical Sciences, ¹⁸National Hospital Organization Kyushu Medical Center, ¹⁹Chiba University, ²⁰Hiroshima University, ²¹National Cancer Center Hospital, ²²National Center for Global Health and Medicine, ²³Shunan Memorial Hospital, ²⁴University of Liverpool, TACTICS study group): Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2019. DOI: 10.1136/gutjnl-2019-318934. [Epub ahead of print]
Koyama T¹, Shimizu T¹, Iwasa S¹, Fujiwara Y¹, Kondo S¹, Kitano S¹, Yonemori K¹, Shimomura A¹, Iizumi S¹, Sasaki T², Furuse J, Yamamoto N¹(¹National Cancer Center Hospital, ²Eisai): First-in-human phase I study of E7090, a novel selective FGFR inhibitor, in patients with advanced solid tumors. Cancer Sci 111(2): 571-579, 2019.
Ueno M¹, Morizane C², Ikeda M³, Okusaka T², Ishii H⁴, Furuse J (¹Kanagawa Cancer Center,²National Cancer Center Hospital, ³National Cancer Center Hospital East, ⁴Chiba Cancer Center): A review of changes to and clinical implications of the eighth TNM classification of hepatobiliary and pancreatic cancers. Jpn J Clin Oncol 249(12): 1073-1082, 2019.
Morizane C¹, Okusaka T¹, Mizusawa J¹, Katayama H², Ueno M³, Ikeda M⁴, Ozaka M⁵, Okano N, Sugimori K⁶, Fukutomi A⁷, Hara H⁸, Mizuno N⁹, Yanagimoto H¹⁰, Wada K¹¹, Tobimatsu K¹², Yane K¹³, Nakamori S¹⁴, Yamaguchi H¹⁵, Asagi A¹⁶, Yukisawa S¹⁷, Kojima Y¹⁸, Kawabe K¹⁹, Kawamoto Y²⁰, Sugimoto R²¹, Iwai T²², Nakamura K²³, Miyakawa H²⁴, Yamashita T²⁵, Hosokawa A²⁶, Ioka T²⁷, Kato N²⁸, Shioji K²⁹, Shimizu K³⁰, Nakagohri T³¹, Kamata K³², Ishii H²³, Furuse J (¹National Cancer Center Hospital, ²Kanagawa Cancer Center, ³National Cancer Center Hospital East, ⁴Cancer Institute Hospital of Japanese Foundation for Cancer Research,⁵Yokohama City University Medical Center, ⁶Shizuoka Cancer Center, ⁷Saitama Cancer Center, ⁸Aichi Cancer Center Hospital, ⁹ Kansai Medical University Hospital, ¹⁰Teikyo University School of Medicine, ¹¹Department of Internal Medicine Kobe University Graduate School of Medicine, ¹²Teine Keijinkai Hospital, ¹³ National Hospital Organization Osaka National Hospital, ¹⁴Jichi Medical University, ¹⁵National Hospital Organization Shikoku Cancer Center, ¹⁶Tochigi Cancer Center,¹⁷National Center for Global Health and Medicine, ¹⁸Kyushu University,¹⁹Hokkaido University Hospital, ²⁰ National Hospital Organization Kyushu Cancer Center, ²¹Kitasato University Hospital, ²²Chiba Cancer Center, ²³Sapporo Kousei General Hospital, ²⁴Kanazawa University, ²⁵University of Toyama, ²⁶Osaka International Cancer Institute, ²⁷Chiba University, ²⁸Niigata Cancer Center Hospital, ²⁹Tokyo Women’s Medical University,³⁰Tokai University School of Medicine, ³¹Tokai University School of Medicine, ³²Kindai University Faculty of Medicine) : Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) Randomized Phase III Clinical Trial. Ann Oncol 30(12):1950-1958, 2019.
Hamauchi S¹, Furuse J, Takano T², Munemoto Y³, Furuya K⁴, Baba H⁵, Takeuchi M⁶, Choda Y⁷, Higashiguchi T⁸, Naito T⁹, Muro K¹⁰, Takayama K¹¹, Oyama S¹², Takiguchi T¹², Komura N¹², Tamura K¹³(¹Shizuoka Cancer Center,²Toranomon Hospital, ³Fukui-ken Saiseikai Hospital,⁴Hokkaido Hospital, ⁵Kumamoto University, ⁶Nagaoka Red Cross Hospital, ⁷Hiroshima Citizens Hospital,⁸Fujita Health University School of Medicine, ⁹Shizuoka Cancer Center, ¹⁰Aichi Cancer Center Hospital,¹¹Kyoto Prefectural University of Medicine, ¹²Ono Pharmaceutical Company, ¹³Fukuoka University) : A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125(23):4294-4302, 2019.
Furuse J: Paradigm shifting of systemic chemotherapy for unresectable pancreatic cancer in Japan. J Clin Med 8(8): 1170, 2019.
Hamaguchi T¹, Denda T², Kudo T³, Sugimoto N⁴, Ura T⁵, Yamazaki K⁶, Fujii H⁷, Kajiwara T⁸, Nakajima TE⁹, Takahashi S¹⁰, Otsu S¹¹, Komatsu Y¹², Nagashima F, Moriwaki T¹³, Esaki T¹⁴,Sato T¹⁵, Itabashi M¹⁶, Oki E¹⁷, Sasaki T¹⁸, Chiron M¹⁹, Yoshino T²⁰(¹National Cancer Center Hospital, ²Chiba Cancer Center,³Osaka University Graduate School of Medicine, ⁴Osaka Medical Center for Cancer and Cardiovascular Disease,⁵Aichi Cancer Center Hospital,⁶Shizuoka Cancer Center, ⁷Jichi Medical University Hospital, ⁸Shikoku Cancer Center, ⁹ Marianna University School of Medicine Hospital, ¹⁰Tohoku University Hospital, ¹¹Oita University Hospital, ¹²Hokkaido University Hospital, ¹³University of Tsukuba Hospital. ¹⁴National Kyushu Cancer Center, ¹⁵Kitasato University East Hospital, ¹⁶Tokyo Women’s Medical University Hospital, ¹⁷Kyushu University Hospital, ¹⁸Sanofi K. K,¹⁹Sanofi, ²⁰National Cancer Center Hospital East): Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Cancer Sci 110(11): 3565-3572, 2019.
Ueno M¹, Nagashima F, Ueno H², Ikeda M³, Ohkawa S¹, Mizuno N⁴, Ioka T⁵, Omuro Y⁶, Nakajima TE⁷ Furuse J (¹Kanagawa Cancer Center, ²National Cancer Center Hospital,³National Cancer Center Hospital East,⁴Aichi Cancer Center Hospital, ⁵Osaka International Cancer Institute, ⁶Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, ⁷ Marianna University School of Medicine Hospital) : Phase I/II study: experience with the late onset of acute pancreatitis after the start of chemotherapy with gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. Intern Med 58(20): 2957-2962, 2019.
Kudo M¹, Ikeda M², Ueshima K¹, Sakamoto M³, Shiina S⁴, Tateishi R², Hasegawa K⁵, Furuse J, Miyayama S⁶, Murakami T⁷, Yamashita T⁸, Kokudo N⁹(¹Kindai University Faculty of Medicine,²National Cancer Center Hospital East,³Keio University School of Medicine, ⁴Juntendo University, ⁵University of Tokyo,⁶Fukuiken Saiseikai Hospital, ⁷Kobe University Graduate School of Medicine, ⁸Kanazawa University, ⁹National Center for Global Health and Medicine) : Response evaluation criteria in cancer of the liver version 5 (RECICL 2019 revised version). Hepatol Res 49(9): 981-989, 2019.
Ueno M¹, Ikeda M², Morizane C³, Kobayashi S¹, Ohno I², Kondo S³, Okano N, Kimura K⁴, Asada S⁴, Namba Y⁴, Okusaka T³, Furuse J (¹Kanagawa Cancer Center, ²National Cancer Center Hospital East, ³National Cancer Center Hospital,⁴Ono Pharmaceutical Co, Ltd): Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol :4(8):611-621, 2019.
Hidaka H¹, Izumi N², Aramaki T³, Ikeda M⁴, Inaba Y⁵, Imanaka K⁶, Okusaka T⁷, Kanazawa S⁸, Kaneko S⁹, Kora S¹⁰, Saito H¹¹, Furuse J, Matsui O¹², Yamashita T⁹, Yokosuka O¹³, Morita S¹⁴, Arioka H¹⁵, Kudo M¹⁶, Arai Y⁷(¹Kitasato University School of Medicine, ²Musashino Red Cross Hospital,³Shizuoka Cancer Center, ⁴National Cancer Center Hospital East, ⁵Aichi Cancer Center Hospital, ⁶Osaka International Cancer Institute,⁷National Cancer Center Hospital, ⁸Okayama University Medical School, ⁹Kanazawa University Hospital, ¹⁰Fukuoka University, ¹¹Asahikawa Kosei General Hospital, ¹²Kanazawa University Graduate School of Medical Science, ¹³Chiba University, ¹⁴ Kyoto University Graduate School of Medicine, ¹⁵Yokohama Rosai Hospita, ¹⁶Kindai University Faculty of Medicine)：Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). Med Oncol 36(6): 52, 2019.
Yamamoto N¹, Ryoo BY², Keam B³, Kudo M⁴, Lin CC⁵, Kunieda F⁶, Ball HA⁶, Moran D⁶, Komatsu K⁷, Takeda K⁶, Fukuda M⁷, Furuse J, Morita S⁸, Doi T⁹(¹National Cancer Center Hospital, ²University of Ulsan, ³Seoul National University Hospital,⁴Kindai University, ⁵ National Taiwan University Hospital,⁶Astellas Pharma Global Development, Inc, ⁷Astellas Pharma, ⁸Kyoto University, ⁹National Cancer Center Hospital East) : A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid Invest New Drugs, 2019. DOI: 10.1007/s10637-019-00780-w. [Epub ahead of print]
Kaibori M¹, Yoshii K², Yokota I², Hasegawa K³, Nagashima F, Kubo S⁴, Kon M⁵, Izumi N⁶, Kadoya M⁷, Kudo M⁸, Kumada T⁹, Sakamoto M¹⁰, Nakashima O¹¹, Matsuyama Y¹², Takayama T¹³, Kokudo N¹⁴(¹Kansai Medical University, ²Kyoto Prefectural University of Medicine, ³ The University of Tokyo ,⁴Osaka City University Graduate School of Medicine , ⁵Musashino Red Cross Hospital,⁶Shinshu University School of Medicine ,⁷Kinki University School of Medicine , ⁸Ogaki Municipal Hospital , ⁹Keio University School of Medicine, ¹⁰Kurume University Hospital,¹¹School of Public Health University of Tokyo, ¹² Nihon University School of Medicine, ¹³National Center for Global Health and Medicine, Liver Cancer Study Group of Japan) : Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma: Report of a Japanese Nationwide Survey. Ann Surg 269(4): 692-699, 2019.
Mizutani T¹, Nakamura K¹, Fukuda H¹, Ogawa A², Hamaguchi T³, Nagashima F (¹ National Cancer Center Hospital,²National Cancer Center Hospital East,³Saitama Medical University International Medical Center, Geriatric Study Committee/Japan Clinical Oncology Group) Geriatric Research Policy: Japan Clinical Oncology Group (JCOG) policy. Japanese Journal of Clinical Oncology 49(10) :901-910, 2019.
Okusaka T¹, Nakamura M², Yoshida M³, Kitano M⁴, Uesaka K⁵, Ito Y⁶, Furuse J, Hanada K⁷, Okazaki K⁸ (¹National Cancer Center Hospital, ²Kyushu University, ³International University of Health and Welfare, ⁴Wakayama Medical University, ⁵Shizuoka Cancer Center,⁶Showa University School of Medicine, ⁷JA Onomichi General Hospital, ⁸Kansai Medical University) Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society: Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis. Pancreas 49(3) :326-335, 2020.
Kudo M¹, Okusaka T², Motomura K³, Ohno I⁴, Morimoto M⁵, Seo S⁶, Wada Y⁷, Sato S⁸, Yamashita T⁹, Furukawa M¹⁰, Aramaki T¹¹, Nadano S¹², Ohkawa K¹³, Fujii H¹⁴, Kudo T¹⁵, Furuse J, Takai H¹⁶, Homma G¹⁶, Yoshikawa R¹⁶, Zhu AX¹⁷(¹Kindai University Faculty of Medicine, ²National Cancer Center Hospital,³Aso Iizuka Hospital, ⁴National Cancer Center Hospital East, ⁵Kanagawa Cancer Center, ⁶Kyoto University, ⁷National Hospital Organization Kyushu Medical Center, ⁸Kyoundo Hospital, Sasaki Institute, ⁹Kanazawa University, ¹⁰National Hospital Organization Kyushu Cancer Center, ¹¹Shizuoka Cancer Center Hospital,¹²National Hospital Organization Shikoku Cancer Center^{, 13}Osaka International Cancer Institute, ¹⁴Jichi Medical University, ¹⁵Osaka University, ¹⁶Eli Lilly Japan K.K, ¹⁷Massachusetts General Hospital Cancer Center) : Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J Gastroenterol 2020. DOI:10.1007/s00535-020-01668-w. [Epub ahead of print]
Okuyama H^1,2, Ikeda M², Okusaka T³, Furukawa M⁴, Ohkawa S⁵, Hosokawa A⁶, Kojima Y⁷, Hara H⁸, Murohisa G⁹, Shioji K¹⁰, Asagi A¹¹, Mizuno N¹², Kojima M¹³, Yamanaka T¹⁴, Furuse J (¹Kagawa University, ²National Cancer Center Hospital East,³National Cancer Center Hospital,⁴National Hospital Organization Kyushu Cancer Center, ⁵Kanagawa Cancer Center, ⁶Faculty of Medicine University of Toyama,⁷National Center for Global Health and Medicine,⁸Saitama Cancer Center, ⁹Seirei Hamamatsu General Hospital, ¹⁰Niigata Cancer Center Hospital, ¹¹National Hospital Organization Shikoku Cancer Center, ¹²Aichi Cancer Center Hospital, ¹³National Cancer Center, ¹⁴Yokohama City University Graduate School of Medicine) : A phase II trial of everolimus in patients with advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy (NECTOR trial). Neuroendocrinology 2020. DOI: 10.1159/000505550. [Epub ahead of print]
Naito Y¹, Mishima S¹, Akagi K², Igarashi A³, Ikeda M¹, Okano S¹, Kato S⁴, Takano T⁵, Tsuchihara K¹, Terashima K⁶, Nishihara H⁷, Nishiyama H⁸, Hiyama E⁹, Hirasawa A¹⁰, Hosoi H¹¹, Maeda O¹², Yatabe Y¹³, Okamoto W⁹, Ono S¹⁴, Kajiyama H¹², Nagashima F, Hatanaka Y¹⁵, Miyachi M¹¹, Kodera Y¹², Yoshino T¹, Taniguchi H¹（¹National Cancer Center Hospital East, ²Saitama Cancer Center, ³Yokohama City University School of Medicine, ⁴Juntendo University, ⁵Tohoku University, ⁶National Center for Child Health and Development, ⁷Keio University, ⁸Tsukuba University, ⁹Hiroshima University Hospital, ¹⁰Okayama University, ¹¹Kyoto Prefectural University of Medicine, ¹²Nagoya University Hospital, ¹³National Cancer Center Hospital, ¹⁴Jichi Medical University, ¹⁵Hokkaido University Hospital）：Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Int J Clin Oncol 25(3) :403-417, 2020.
Okusaka T¹, Nakamura M², Yoshida M³, Kitano M⁴, Uesaka K⁵, Ito Y⁶, Furuse J, Hanada K⁷, Okazaki K⁸(¹National Cancer Center Hospital, ²Kyushu University,³International University of Health and Welfare,⁴Wakayama Medical University, ⁵Shizuoka Cancer Center,⁶Showa University School of Medicine,⁷JA Onomichi General Hospital, ⁸Kansai Medical University, Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society): Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis. Pancreas 49(3): 326-335, 2020.
Kitamura H, Nagashima F, Andou M¹, Furuse J (¹Nagoya University): Feasibility of Continuous Geriatric Assessments as a Prognostic Indicator in Elderly People with Gastrointestinal Cancer. Intern Med 59(1): 15-22, 2020.
Okano N, Naruge D, Kawai K, Kobayashi T, Nagashima F, Endou H¹, Furuse J (¹J-Pharma Co): First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2020. DOI: 10.1007/s10637-020-00924-3. [Epub ahead of print]
Kitamura H, Nagashima F, Andou M¹, Furuse J (¹Nagoya University): Feasibility of Continuous Geriatric Assessments as a Prognostic Indicator in Elderly People with Gastrointestinal Cancer. Intern Med 59(1): 15-22, 2020.

和文

古瀬純司：ラムシルマブとほかの二次治療薬との使い分け．特集／進化する肝細胞癌の薬物療法―2019 Update (Part 1)．肝胆膵 79(2): 344-349, 2019.
古瀬純司，上野誠¹，石井浩² (¹神奈川県立がんセンター・消化器内科，²千葉県がんセンター・治験臨床研究センター)：がん治療における患者参画．医師の立場からの期待．癌と化学療法 46(8): 1230-1234, 2019.
岡野尚弘，古瀬純司：アテゾリズマブ + ベバシズマブ併用Phase Ib試験のUpdated data. 特集／進化する肝細胞癌の薬物療法―2019 Update (Part 2). 肝胆膵 79(3): 587-591, 2019.
古瀬純司：レンバチニブ+ ペムブロリズマブ併用療法の第Ⅰb相試験-Updated data. 特集／進化する肝細胞癌の薬物療法―2019 Update (Part 2)．肝胆膵 79(2): 597-600, 2019.
古瀬純司：胆道癌・膵癌に対する免疫療法の現状と展望．消化器・肝臓内科 6(3): 218-223, 2019.
古瀬純司：第55回米国臨床腫瘍学会(ASCO2019) meeting report. The Liver Cancer Journal 11(2): 55-58, 2019.
古瀬純司：術前治療としての化学療法の動向．胆と膵 40(11): 957-961, 2019.
岡野尚弘，長島文夫，古瀬純司：消化器癌のゲノム医療．杏林医学会誌50(4): 191-197, 2019.

著　書

古瀬純司（分担執筆）：膵癌．膵腫瘍と嚢胞性膵疾患．消化管・腹膜疾患肝・胆道・膵疾患. 内科学書改訂第9版. 南学正臣総編集．東京，中山書店，2019．475-479．
古瀬純司，岡野尚弘（分担執筆）：胆道癌に対するアキシチニブ単独療法の治療開発(B44)．先進医療NAVIGATOR．がん先進医療の最前線．先進医療フォーラム編集．東京，日本医学出版，2019．60-64.
長島文夫（ガイドライン作成統括委員会副委員長）：高齢者のがん薬物療法ガイドライン．日本臨床腫瘍学会/日本癌治療学会編．東京，南江堂，2019．
長島文夫（評価委員）：成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン第2版．日本癌治療学会/日本臨床腫瘍学会編．東京，金原出版，2019．
岡野尚弘（分担執筆）：XELOX(CapeOX)療法．消化器ナーシング. 東京，メディカ出版， p. 35-37.
岡野尚弘（分担執筆）：アテゾリズマブ＋ベバシズマブ併用phase Ib試験のuodated data.　肝胆膵．東京，アークメディア，2019．587-591.
岡野尚弘（分担執筆）：GEM＋CDDP (GC). 消化器がん化学療法副作用マネジメントプロのコツ改訂第2版．東京，メジカルビュー社，2019．168-171.
岡野尚弘（分担執筆）：GEM＋S-1(GS)．消化器がん化学療法副作用マネジメントプロのコツ改訂第2版．東京，メジカルビュー社，2019．172-175.
岡野尚弘（分担執筆）：胆道癌におけるFGFR遺伝子異常とFGFR阻害薬の開発．胆と膵．東京，医学図書出版，2019．1347-1350.
岡野尚弘（分担執筆）：肝・胆・膵がんにおけるMSI検査の位置づけ．腫瘍内科．東京，化学評論社，2019．219-224．

報告書

長島文夫：高齢がん患者に対する簡便で効果的な診療プログラムの開発．厚生労働科学研究費補助金 (がん対策推進総合研究事業)2019年度　分担研究報告書．
長島文夫：高齢者がん診療指針策定に必要な基盤整備に関する研究．厚生労働科学研究費補助金 (がん対策推進総合研究事業)2019年度　分担研究報告書．

その他

【座長・司会・主催】

古瀬純司（座長）：外来化学療法カンファレンス. 武蔵野, 2019年4月5日.
窪田敬一、古瀬純司（司会）: Borderline resectable膵がんに対する治療戦略.金沢, 第105回日本消化器病学会総会, 金沢, 2019年5月10日.
古瀬純司、廣岡芳樹 (座長)：膵疾患に対する造影超音波検査の有用性と今後の展開. Ultrasonic Week 2019. 日本超音波医学会第92回学術集会, 東京, 2019年5月24日.
古瀬純司（司会）：ランチョンセミナー. 第108回日本消化器内視鏡学会関東支部例会, 東京, 2019年6月8日.
古瀬純司 (座長)：Gastric Cancer I-O Seminar in Tama. Lecture. 立川, 2019年6月24日.
古瀬純司 (座長)：GEP-NET Web Seminar. 東京, 2019年6月26日.
古瀬純司 (座長)：Colorectal Cancer Conference. 立川, 2019年6月27日.
古瀬純司、永井英成（司会）: レンバチニブによる新たな肝細胞癌治療ストラテジー. 第20回日本肝がん分子標的治療研究会, 長崎, 2019年6月29日.
古瀬純司 (司会): ランチョンセミナー第55回日本肝癌研究会, 東京, 2019年7月5日.
古瀬純司（司会）: 特別講演第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
高折恭一、古瀬純司（司会）: PanCan Award. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
Furuse J（司会）: Guidelines for pancreatic cancer, Japan vs. USA. Luncheon Seminar. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
岡崎和一、古瀬純司（司会）: 日本膵臓学会-昨日から明日へ. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
古瀬純司（司会）: 英語発表上達のコツ. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
長島文夫 (司会) : 膵癌に対する内視鏡治療～疼痛・症状緩和を目指して～. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
Furuse J, Ueno M(司会) : New evidence of chemotherapy in biliary tract and pancreatic cancers and introduction them to the practice. 第17回日本臨床腫瘍学会学術集会, 京都, 2019年7月19日.
古瀬純司（司会）：メディカルセミナー第17回日本臨床腫瘍学会学術集会, 京都, 2019年7月19日.
Cheng AL, Furuse J (座長) : Sponsored Symposium 2. The role of Systemic Therapy for uHCC. The 10th Asia-Pacific Primary Liver Cancer Expert Meeting, 札幌, 2019年8月31日.
古瀬純司 (主催)：第50回日本膵臓学会大会　市民公開講座. 東京，2019年8月4日．
古瀬純司（Opening remarks）：がん包括マネジメントセミナー. 三鷹, 2019年9月18日.
古瀬純司（司会）: 膵癌診療ガイドライン改訂後のこれからの治療戦略. 高齢者膵癌に対する治療戦略を考える. 第57回日本癌治療学会学術集会, 福岡, 2019年10月24日.
山本雅一、吉田雅博、古瀬純司（司会）: 転移性肝癌国際診療ガイドライン公聴会. 第57回日本癌治療学会学術集会, 福岡, 2019年10月24日.
矢永勝彦、古瀬純司: 臓器別シンポジウム Borderline Resectable膵癌に対する治療戦略. 第57回日本癌治療学会学術集会, 福岡, 2019年10月25日.
古瀬純司（司会）：血管新生阻害薬, 東京, 2019年10月31日.
Furuse J, Brand R（座長）: Mini Symposium IV. Genomics of exocrine pancreatic disorders. APA-JPS joint meeting in 2019, USA, November 7th-9th,2019.
Qin S, FuruseJ, Paark JO: Hepatobiliary-Pancreatic Cancer Session. 7^th Federation of Asian Clinical Oncology (FACO) Academic Conference, China, December 6th,2019.
古瀬純司（司会）：10周年特別企画2．第21回日本肝がん分子標的治療研究会，東京，2020年1月11日．
古瀬純司、吉岡祐亮（司会）: ゲノム医療の時代におけるリキッドバイオプシーの役割. 第4回リキッドバイオプシー研究会. 東京, 2020年1月17-18日.
古瀬純司（司会）: Patient and Public Involvement, PPI. JCOG-EORTC symposium. 東京, 2020年2月15日.
古瀬純司（座長）：がん疼痛セミナー, がん疼痛治療の最前線. 三鷹, 2019年2月28日.

【新聞掲載】

長島文夫：「質問なるほドリ、乳がんになる高齢者って多いの？」にて解説，毎日新聞，2019年8月31日．
長島文夫：「医療の意思決定、高齢者のがん・後編」にて解説，読売新聞，2019年11月25日．
長島文夫：「がん5年生存率病期・年代別公表」にて解説，朝日新聞，2019年12月14日．

講　演

古瀬純司 : 膵・消化管神経内分泌腫瘍の薬物療法-多様な治療をどう使い分ける？．膵・消化管神経内分泌腫瘍を考える,新潟,2018年4月12日.
Furuse J : Adjuvant therapy experience-including S-1. Pancreas 2018, USA, April 26th-28th, 2018.
古瀬純司 : 肝細胞がんの化学療法ー新時代への展望. LENVIMA-HCC　適応追加記念講演会, 長崎, 2018年5月16日.
古瀬純司：消化器がんにおけるPrecision Medicine.GI-SCREENと多摩地区の現状と今後.第6回KDOG meeting, 町田, 2018年5月19日.
古瀬純司：神経内分泌腫瘍に対する薬物療法ー最新の情報と今後の展望.第10回Tohoku-NET WORK, 仙台, 2018年5月26日.
Okano N, Kawai K, Kobayashi T, Nagashima F, Endou H, Furuse J： First-in-human phase I study of JPH203, L-type amino acids transporter 1 inhibitor, in patients with advanced solid tumors. ASCO 2018 annual meeting, USA, June 1st-6th, 2018.
Tsuji Y, Shitara K, Yamanaka T, Denda T, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi A, Yoshino T: REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis. ASCO 2018 annual meeting, USA, June 1st-6th, 2018.
Ueno M, Morizane C, Okusaka T, Mizusawa J, Katayama H, Ikeda M, Ozaka M, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Sano K, Tobimatsu K, Yane K, Nakamori S, Sata N, Yukisawa S, Ishii H, Furuse J: Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). ASCO 2018 annual meeting, USA, June 1st-6th, 2018.
Kudo M, Ueshima K, Torimura T, Tanabe N, Ikeda M, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Isoda N, Yasui K, Kuzuya T, Okusaka T, Furuse J, Kokudo N, Okita K, Yoshimura K, Arai Y, TACTICS Trial Group: Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. ASCO 2018 annual meeting, USA, June 1st-6th,2018.
Abou-Alfa GK, Chan SL, Furuse J, Galle PR, Kelley RK, Qin S, Armstrong J, Darilay A, Vlahovic G, Negro A, Sangro B: A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. ASCO 2018 annual meeting, USA, June 1st-6th, 2018.
Okano N, Kawai K, Kobayashi T, Nagashima F, Endou H, Furuse J: First-in-human

phase I study of JPH203, L-type amino acids transporter 1 inhibitor, in patients with advanced solid tumors. ASCO 2018 annual meeting, USA, June 1st-6th, 2018.

古瀬純司, 奥坂拓志, 小西大 : 胆道癌診療ガイドライン公聴会. 化学療法. 第30回日本肝胆膵外科学会学術集会, 横浜, 2018年6月7-9日.
古瀬純司 : 肝細胞癌の分子標的治療：ソラフェニブ単独から多様な治療選択へ. 第30回日本肝胆膵外科学会学術集会, 横浜, 2018年6月7-9日.
Furuse J: The 2nd line chemotherapy in Japan and future perspectives. The 11^th International Pancreatic Cancer Conference, Commemorative Lecture of Pin-Wen Lin and 2018 Cancer Biology Symposium, Taiwan, June 8th-10th, 2018.
Furuse J: The experience of FOLFIRINOX in advanced pancreatic cancer. Japanese experience. Satellite Symposium in the 11^th International Pancreatic Cancer Conference, Taiwan, June 8th-10th, 2018.
古瀬純司 : 特別講演.肝細胞がんの薬物療法ー新時代への展望. LENVIMA-HCC AE Management Forum in Dokkyo, 栃木, 2018年6月13日.
長島文夫 : 高齢者のがん患者を診療するにあたっての考え方. 第60回日本老年医学会学術集会, 京都, 2018年6月16日.
古瀬純司 : 特別講演.肝細胞がんの薬物療法ー新時代への展望. Lenvatinib適応追加記念講演会, 金沢, 2018年6月21日.
岡部直太, 小林敬明, 千葉知宏, 大窪泰弘, 古瀬純司, 草間博 : 食道悪性黒色腫に対するnivolumab治療中にリンパ球性下垂体炎を来した剖検症例の一例. 第107回日本病理学会総会, 札幌, 2018年6月21-23日
長島文夫：高齢者に抗がん剤は効果なし”は本当なのか?. 日本臨床腫瘍学会市民公開講座, 大阪, 2018年6月24日.
古瀬純司 : 切除不能膵癌における治療方針－conversion surgeryの是非－. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
岡野尚弘, 西岡真理子, 前園知宏, 河合桐男, 小林敬明, 長島文夫, 古瀬純司 : 遠隔転移を有する膵癌における化学療法によるconversion surgery. 切除不能膵癌における治療方針－conversion surgeryの是非－. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
古瀬純司 : 切除不能膵癌に対する化学療法-ガイドラインにおける課題. 特別企画2膵癌ガイドラインの諸問題と今後の課題. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
西岡真理子, 岡野尚弘, 前園知宏, 河合桐男, 小林敬明, 長島文夫, 古瀬純司: FOLFIRINOXとGEM耐性後、GEM+na-PTX療法が奏効した肝転移を伴う膵癌の1例. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
前園知宏, 岡野尚弘, 西岡真理子, 河合桐男, 小林敬明, 長島文夫, 古瀬純司: GEM+nab-PTX不応後にmodified FOLFIRINOXが著効したBRCA1遺伝子変異を有した切除不能膵癌の1例. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
山内芳也, 西岡真理子, 前園知宏, 河合桐男, 小林敬明, 岡野尚弘, 長島文夫, 古瀬純司 : 切除不能・再発膵腺扁平上皮癌に対する併用薬物療法施行例の検討. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
古瀬純司 : 特別講演.肝細胞がんの薬物療法ー新時代への展望.鹿児島LENVIMA-HCC適応追加記念講演会, 鹿児島, 2018年7月4日.
Furuse J, Chan SL, Sangro B, Galle PR, Kelley RK, Qin S, Armstrong J, Darilay A, Vlahovic G, Xu Y, Negro A, Abou-Alfa GK, on behalf of the HIMALAYA investigators: HIMALAYA study: a randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC). the 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2018), Korea, July 6th-8th, 2018.
Furuse J, Hamauchi S, Takano T, Munemoto Y, Furuya K, Baba H, Takeuchi M, Choda Y, Higashiguchi T, Naito T, Muro K, Takayama K, Tamura K: A multicenter, open-label, uncontrolled study of ONO-7643/anamorelin in cachexia patients with gastrointestinal cancer. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
山内理海, 設楽紘平, 山中竹春,傳田忠道, 辻靖, 小松嘉人, 小林良充, 古瀬純司, 加藤健志, 沖英次, 安藤高志, 萩原康博, 大橋靖雄, 吉野孝之: REVERCE: Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Metastatic Colorectal Cancer Patients Previously Treated with Fluoropyrimidine, Oxaliplatin, and Irinotecan: Quality of Life Analysis. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
奥坂拓志, 池田公史, 大野泉, 高橋秀明, 近藤俊輔, 森実千種, 古瀬純司 : 肝細胞がん患者を対象としたGPC3, WDRPUH及びNEIL3由来ペプチドワクチンの第1相試験における最終解析. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
小山隆文, 清水俊雄, 藤原豊, 近藤俊輔, 北野滋久, 米盛勧, 下村昭彦, 飯泉桜, 佐々木達也, 古瀬純司, 山本昇 : 新規FGFR選択的阻害薬E7090の進行固形癌患者を対象とした第1相臨床試験. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
工藤敏啓, 川本泰之, 奥坂拓志, 高橋秀明, 小林智, 古瀬純司, 伊藤心二, 清水怜, 中村和貴, 鎌田研, 衣斐寛倫, 伊藤直樹, 水野伸匡, 石井浩, 森実千種,吉野孝之 : The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN (GI-SCREEN 2015-01-Non CRC) Advanced Biliary Tract Cancer Cohort. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
長島文夫, 古瀬純司 : JSMO-SIOG symposium All oncologists are geriatric oncologists Geriatric Oncology in Japan. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
清水怜, 高橋秀明, 上野誠, 大場彬博, 村中徹人, 須藤研太郎, 岡野尚弘, 水上拓郎, 伊藤心二, 石井浩, 賀川義規, 鎌田研, 工藤敏啓, 森実千種, 吉野孝之 : The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Advanced Pancreatic Cancer Cohort. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
山内芳也, 西岡真理子, 前園知宏, 河合桐男, 小林敬明, 岡野尚弘, 成毛大輔, 北村浩, 女屋博昭, 長島文夫, 古瀬純司 : 高齢者膵がんにおけるCTを利用した筋肉の評価と薬物療法の臨床的アウトカムに関する研究. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
古瀬純司 : 膵がんの基礎知識と治療の最新情報. ONCOLO Meets Cancer Experts eminar, 東京, 2018年7月27日.
古瀬純司 : 消化器癌化学療法の最新情報. ASCO 2018より. 三鷹キャンサーネット, 三鷹, 2018年8月2日.
古瀬純司 : 膵・消化管神経内分泌腫瘍の新たな展開ー診断から治療まで. 膵・消化管神経内分泌腫瘍セミナー, 宮崎,2018年8月3日.
古瀬純司 : 肝細胞がんの薬物療法ー新時代への展望.滋賀LENVIMA適正使用講演会, 草津,2018年8月30日.
北村浩, 長島文夫, 岡野尚弘, 中澤潤一, 有馬志穂, 古瀬純司 : Gemcitabine baseの化学療法を行った高齢者膵がんにおける有害事象と高齢者機能評価について．第3回日本がんサポーティブケア学会, 福岡, 2018年8月31日.
前野聡子, 長島文夫, 河合桐男, 前園知宏, 黒澤貴志, 小林敬明, 岡野尚弘, 北村浩, 有馬志穂, 古瀬純司：海外高齢者がん診療ガイドライン活用の工夫－認知症をもつがん患者の実地症例から－. 第3回日本がんサポーティブケア学会, 福岡, 2018年8月31日.
Sangro B, Chan SL, Furuse J, Galle PR, Kelley RK, Qin S, Armstrong J, Darilay A, Vlahovic G, Xu Y, Negro A, Abou-Alfa G: A Randomized, Multicenter Phase 3 Study of Durvalumab (D) and Tremelimumab (T) as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma (HCC): HIMALAYA Study. ILCA Annual Conference, UK, September 14th-16th, 2018.
Ueshima K, Kudo M, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Arai Y and TACTICS study group: Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. ILCA Annual Conference, UK, September 14th-16th, 2018.
Kobayashi S, Terashima T, Shiba S, Yoshida Y, Yamada I, Iwadou S, Horiguchi S, Takahashi H, Suzuki E, Moriguchi M, Tsuji K, Otsuka T, Asagi A, Kojima Y, Takada R, Ueno M, Morizane C, Mizuno N, Ikeda M, Furuse J: Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and ILCA Annual Conference, UK, September 14th-16th, 2018.
古瀬純司, 奥坂拓志, 小西大, 山崎秀哉 : 胆道癌診療ガイドライン公聴会. 化学療法、放射線療法. 第54回日本胆道学会学術集会, 千葉, 2018年9月27-28日.
Furuse J: Systemic treatment for advanced HCC－Current status and future perspectives. Taiwan Digestive Disease Week 2018. Taiwan, September 29th-30th, 2018.
古瀬純司：最新のがん治療：ゲノム医療の幕開け. 杏林大学病院がんセンター「がんと共にすこやかに生きる」講演会シリーズ第4回, 三鷹, 2018年10月13日.
古瀬純司, 岡野尚弘, 黒澤貴志 : 初診時切除不能膵癌に対するconversion surgery
－内科の立場から. 第56回日本癌治療学会学術集会, 横浜, 2018年10月18-20日.
Furuse J: Cohort study of patients with initially unresectable pancreatic cancer of conversion surgery after FOLFIRINOX or GEM plus nab-PTX (PC-CURE-1). 6th International Conference of FACO. 第56回日本癌治療学会学術集会, 横浜, 2018年10月18-20日.
Denda T, Shitara K, Yamanaka T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Kato T, Ohashi Y, Yoshino T: REVERCE: A Randomized Phase II of Regorafenib- Cetuximab for mCRC previously treated with chemotherapy: serum protein biomarker analysis. 第56回日本癌治療学会学術集会, 横浜, 2018年10月18日-20日.
Kitamura H, Nagashima F, Andou M, Nakazawa J, Arima S, Okano N, Furuse J: Cancer-Specific Geriatric Assessment(CSGA)を用いた高齢者膵癌化学療法の第二相試験. 第56回日本癌治療学会学術集会, 横浜, 2018年10月18-20日.
Izawa N, Morizane C, Takahashi H, Ueno M, Kawamoto Y, Okano N, Shimizu S, Sudo K, Itoh S, Asagi A, Y. Kagawa, K. Kamata, T. Kudo, S. Nomura, T. Kuwata, S. Fujii, W. Okamoto, K. Shitara, A. Ohtsu, T. Yoshino: The nationwide cancer genome screening project in Japan, SCRUM Japan GISCREEN: Efficient identification of cancer genome alterations in advanced biliary tract cancer. ESMO 2018, Germany, October 19th-23rd, 2018.
Takahashi H, Morizane C, Nomura S, Okano N, Tsuda M, Mizuno N, Satake K, Tsuji K, Shioji K, Ishii H, Yasui K, Miyakawa H, Ishiguro A, Ogura T, Ueno M, Ikeda A, Terashima T, Ikeda M, Okusaka T, Furuse J: Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). ESMO 2018, Germany, October 19th-23rd,2018.
Okuyama H, Ikeda M, Okusaka T, Furuse J, Furukawa M, Ohkawa S, Hosokawa A, Kojima Y, Yamaguchi K, Murohisa G, Shioji K, Ishii H, Mizuno N, Kojima M, Yamanaka T: A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-contained chemotherapy. Germany, ESMO 2018, October 19th-23rd, 2018.
長島文夫 : 本当!? 「高齢者に抗がん剤は“効果なし?”」. ちゃやまちキャンサーフォーラム2018, 大阪, 2018年10月27日.
古瀬純司 : 膵癌治療の最前線―エビデンスとプラクティス. 第16回日本消化器外科学会大会, 神戸, 2018年11月1-4日.
古瀬純司 : 切除不能肝内胆管癌の化学療法―現状と今後の展望. 第16回日本消化器外科学会大会, 神戸, 2018年11月1-4日.
古瀬純司 : 膵癌の化学療法ー最新の動向と今後の展望. Osaka GI Oncology Forum, 大阪, 2018年11月16日.
古瀬純司 : 膵癌の化学療法ー最新の動向と今後の展望. 第15回京都消化器癌化学療法研究会, 京都, 2018年11月22日.
FuruseJ: Chemotherapy for unresectable pancreatic cancer－Current status and future perspectives. The 8th Japan-China Hepato-Pancreato-Biliary Symposium,,Tokyo, November 22ed-23rd, 2018.
古瀬純司 : 膵・胆道癌化学療法の最新情報ーがんゲノム医療の導入は？．第17回大阪消化器化学療法懇話会, 大阪, 2018年12月1日.
古瀬純司 : 特別講演.膵癌化学療法の最新の知見. Pancreatic Cancer and Neuroendocrine tumor FORUM in Chiba, 千葉, 2018年12月14日.
古瀬純司：消化器癌化学療法の最近の話題-ESMO2018 in Munich. 三鷹キャンサーネット, 三鷹, 2018年12月20日.
古瀬純司：膵がん治療の最前線－新しいガイドラインと今後の期待. パンキャンジャパン膵がん勉強会クリスマス・スペシャル, 東京, 2018年12月22日.
Chow PKH, Li L, Li J, Jia F, Wang HJ, Hasegawa K, Yang JM, Tan PS, Qin S, Han KH, Goh B, Han HS, Furuse J, Zhu X, Ling JZJ, Gandhi M: Differences in Presentation and Management Patterns in Patients with Hepatocellular Carcinoma (HCC): Data from HCC Registry in Asia. 2019 Gastrointestinal cancers symposium, USA, January 17th-19th,2019.
Kobayashi S, Ueno M, Ogawa G, Fukutomi A, Ikeda M, Okusaka T, Sato T, Ito Y, Kadota T, Ioka T, Sugimori K, Sata N, Nakamori S, Shimizu K, Mizuno N, Ishii H, Furuse J: Impact of renal function on the efficacy and safety of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer: an integrated exploratory analysis of JCOG1106 and LAPC-S1RT. 2019 Gastrointestinal cancers symposium, USA, January 17th-19th, 2019.
Ikeda M, Ueno M, Morizane C, Kobayashi S, Ohno I, Kondo S, Okano N, Kimura K, Asada S, Namba Y, Okusaka T, Furuse J: A multicentre open-label, phase 1 study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer. 2019 Gastrointestinal cancers symposium, USA, January 17th-19th, 2019.
Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX: Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein Following First-Line Sorafenib: Pooled Efficacy and Safety in Japanese Patients Across Two Global Randomized Phase 3 Studies (REACH-2 and REACH). 2019 Gastrointestinal cancers symposium, January 17th-19th, 2019.
Yamada I, Morizane C, Okusaka T, Ogawa G, Sato Y, Ueno M, Ikeda M, Sugimori K, Fukutomi A, Shimizu S, Mizuno N, Yanagimoto H, Sano K, Tobimatsu K, Yane K, Nakamori S, Sata N, Nishina T, Ishii H, Furuse J: The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: An exploratory analysis of JCOG1113. 2019 Gastrointestinal cancers symposium, January 17th-19th, 2019.
Ueno M, Morizane C, Okusaka T, Ogawa G, Sato Y, Ikeda M, Ozaka M, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Sano K, Tobimatsu K, Yane K, Nakamori S, Sata N, Nishina T, Ishii H, Furuse J: The influence of renal function on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory analysis of JCOG1113. 2019 Gastrointestinal cancers symposium, January 17th-19th, 2019.
Goyal L, Bahleda R, Furuse J, Valle J, Markus Moehler M, Oh DY, Chang HM, Kelley RK, Javle M, Borad M, Chen LT, Uboha N, Klümpen HJ, O’Dwyer PJ, Li D, Morizane C, Huang J, Bridgewater JA: FOENIX-CCA2 (FOENIX-101): A phase 2 trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions and other rearrangements. 2019 Gastrointestinal cancers symposium, January 17th-19th, 2019.
長島文夫 : 高齢者のがん治療. 健康長寿講演会（三鷹市老人クラブ連合会）, 三鷹, 2019年2月5日.
長島文夫 : みんなで支えるがん医療「超高齢社会とがん、杏林CCRC研究所の取り組み」. 杏林CCRCフォーラム公開講演会, 三鷹, 2019年2月23日.
長島文夫 : 高齢者とがん. 杏林大学講演会シリーズ第7回「がんと共にすこやかに生きる」, 三鷹, 2019年3月2日.
古瀬純司 : 消化器がんに対するがんゲノム医療. 日本癌治療学会第18回アップデート教育コース, がん治療とゲノム医療, 三鷹, 2019年3月9日.
Furuse J: Consolidating the Treatment Guidelines of Chemotherapy for Cholangiocarcinoma between the East and West. Lecture. 3^rd Asian-Pacific Cholangiocarcinoma Conference. Taiwan, March 15th-16th, 2019.
長島文夫 : 第2回老年腫瘍学セミナー. 日本臨床腫瘍学会,東京, 2019年3月21日.

論　文

欧文

Kitahara H¹, Honma Y¹, Ueno M², Kanemitsu Y¹, Ohkawa S², Mizusawa J¹, Furuse J, Shimada Y³, Colorectal Cancer Study Group and Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (¹National Cancer Center Hospital, ²Kanagawa Cancer Center,³Kochi Health Sciences Center) : Randomized phase III trial of post-operative chemotherapy for patients with stage I/II/III small bowel adenocarcinoma (JCOG1502C, J-BALLAD). Jpn J Clin Oncol, 2018. DOI:10.1093/jjco/hyy188. [Epub ahead of print]
Doi T¹, Yoh K¹, Shitara K¹, Takahashi H¹, Ueno M², Kobayashi S², Morimoto M², Okusaka T¹, Ueno H¹, Morizane C¹, Okano N, Nagashima F, Furuse J (¹National Cancer Center Hospital East, ²Kanagawa Cancer Center)：First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors. Invest New Drugs, 2018. DOI: 10.1007/s10637-018-069 7-3. [Epub ahead of print]
Shiba S¹, Imaoka H², Shioji K³, Suzuki E⁴, Horiguchi S⁵, Terashima T⁶, Kojima Y⁷, Okuno T⁸, Sukawa Y⁹, Tsuji K¹⁰, Umemoto K¹¹, Asagi A¹², Todaka A¹³, Ueno M¹⁴, Ikeda M¹¹, Morizane C¹, Furuse J（¹National Cancer Center Hospital, ²Aichi Cancer Center Hospital, ³Niigata Cancer Center Hospital, ⁴Chiba University, ⁵Okayama University Graduate School of Medicine, ⁶Kanazawa University Hospital, ⁷National Center for Global Health and Medicine, ⁸Kinki University, ⁹Keio University, ¹⁰Teine Keijinkai Hospital, ¹¹National Cancer Center Hospital East, ¹²Shikoku Cancer Center, ¹³Shizuoka Cancer Center, ¹⁴ Kanagawa Cancer Center）：Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study. BMC Cancer 18(1) : 993,2018.
Tak WY¹, Ryoo BY², Lim HY³, Kim DY⁴, Okusaka T⁵, Ikeda M⁶, Hidaka H⁷, Yeon JE⁸, Mizukoshi E⁹, Morimoto M¹⁰, Lee MA¹¹, Yasui K¹², Kawaguchi Y¹³, Heo J¹⁴, Morita S¹⁵, Kim TY¹⁶, Furuse J, Katayama K¹⁷, Aramaki T¹⁸, Hara R¹⁹, Kimura T¹⁹, Nakamura O¹⁹, Kudo M²⁰(¹Kyungpook National University, ²University of Ulsan College of Medicine,³Sungkyunkwan University , ⁴Yonsei University College of Medicine , ⁵National Cancer Center Hospital, ⁶National Cancer Center Hospital East , ⁷Kitasato University Hospital , ⁸Korea University Guro Hospital , ⁹Kanazawa University Hospital, ¹⁰Kanagawa Cancer Center, ¹¹The Catholic University of Korea, ¹²Kyoto Prefectural University of Medicine , ¹³Saga-ken Medical Centre Koseikan , ¹⁴Pusan National University and Medical Research Institute , ¹⁵Kochi Health Sciences Center , ¹⁶Seoul National University Hospital , ¹⁷Osaka International Cancer Institute , ¹⁸Shizuoka Cancer Center, ¹⁹Yakult Honsha , ²⁰Kindai University Hospital )：Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. Invest New Drugs 36(6) : 1072-1084, 2018.
Mizusawa J¹, Fukutomi A², Katayama H¹, Ishii H³, Ioka T⁴, Okusaka T¹, Ueno H¹, Ueno M⁵, Ikeda M⁶, Mizuno N⁷, Ozaka M⁸, Fukuda H¹, Furuse J, Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (¹National Cancer Center Hospital, ²Shizuoka Cancer Center, Shizuoka, ³National Hospital Organization Shikoku Cancer Center, ⁴Osaka International Cancer Institute, ⁵Kanagawa Cancer Center, ⁶National Cancer Center Hospital East, ⁷Aichi Cancer Center Hospital,⁸Cancer Institute Hospital of the Japanese Foundation for Cancer Research)：Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407). Pancreatology 18(7) : 841-845,2018.
Morizane C¹, Ueno M², Ikeda M³, Okusaka T², Ishii H⁴, Furuse J (¹National Cancer Center Hospital,²Kanagawa Cancer Center, ³National Cancer Center Hospital East, ⁴National Hospital Organization Shikoku Cancer Center)：New developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin Oncol 48(8) : 703-711,2018.
Kobayashi S¹, Terashima T², Shiba S³, Yoshida Y⁴, Yamada I⁵, Iwadou S⁶, Horiguchi S⁷, Takahashi H⁸, Suzuki E⁹, Moriguchi M¹⁰, Tsuji K¹¹, Otsuka T¹², Asagi A¹³, Kojima Y¹⁴, Takada R¹⁵, Morizane C³, Mizuno N¹⁶, Ikeda M⁸, Ueno M¹, Furuse J（¹Kanagawa Cancer Center,²Kanazawa University Hospital, ³National Cancer Center Hospital,⁴ Shizuoka Cancer Center, ⁵Cancer Institute Hospital of the Japanese Foundation for Cancer Research, ⁶Hiroshima City Hospital,⁷Okayama University, ⁸National Cancer Center Hospital East, ⁹Chiba University,¹⁰Kyoto Prefectural University of Medicine, ¹¹Ishikawa Prefectural Central Hospital, ¹²Saga University Hospital, ¹³National Hospital Organization Shikoku Cancer Center, ¹⁴National Center for Global Health and Medicine, ¹⁵Osaka International Cancer Institute, ¹⁶Aichi Cancer Center Hospital）：Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci 109(8) : 2549-2557,2018.
Nakachi K^1,2, Konishi M¹, Ikeda M³, Shimada K³, Okusaka T³, Saiura A⁴, Ishii H⁴, Sugiyama M⁵, Furuse J, Sakamoto H⁵, Shimamura T⁵, Ohta T⁶(¹National Cancer Center Hospital East,²Otaru General Hospital, ³National Cancer Center Hospital, ⁴Cancer Institute Hospital of the Japanese Foundation for Cancer Research,⁵Saitama Cancer Center, ⁶Tokyo Women’s Medical University)：Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer. Int J Clin Oncol 23(5) : 894-899,2018.
Sato Y^1,2, Ueno H³, Ioka T⁴, Ohkawa S⁵, Ikeda M⁶, Shimamura T⁷, Tsuji A⁸, Tsuchiya Y⁹, Furuse J¹⁰, Ishii H¹¹, Furuya K¹², Iguchi H¹³, Saito Y¹⁴, Kaniwa N¹⁴, Sawada JI¹⁴, Sakamoto H¹, Sekine A^2, Okusaka T³, Yoshida T¹(¹National Cancer Center Research Institute,²Chiba University, ³National Cancer Center Hospital, ⁴Osaka Medical Center for Cancer and Cardiovascular Disease, ⁵Kanagawa Cancer Center, ⁶National Cancer Center Hospital East,⁷East Medical Clinic, ⁸Kagawa University, ⁹Niigata Cancer Center Hospital, ¹⁰ Kyorin University,¹¹Cancer Institute Hospital,¹²Hokkaido Social Insurance Hospital, ¹³Sasebo Kyosai Hospital, ¹⁴National Institute of Health Sciences) : GEST. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Pancreas 47(5):637-642，
Furuse J, Shibahara J¹, Sugiyama M²(¹Department of Pathology, Kyorin university, ² Department of Surgery, Kyorin university)：Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. J Hepatobiliary Pancreat Sci 25(5) : 261-268, 2018.
Ozaka M¹, Ishii H², Sato T³, Ueno M⁴, Ikeda M⁵, Uesugi K⁶, Sata N⁷, Miyashita K⁸, Mizuno N⁹, Tsuji K¹⁰, Okusaka T¹⁰, Furuse J：（¹Cancer Institute Hospital of the Japanese Foundation for Cancer Research,²National Hospital Organization Shikoku Cancer Center, ³Kyoto University School of Public Health, ⁴Kanagawa Cancer Center, ⁵National Cancer Center Hospital East, ⁶Jichi Medical University School of Medicine, ⁷Showa University Northern Yokohama Hospital,⁸Aichi Cancer Center Hospital, ⁹Ishikawa Prefectural Central Hospital, ¹⁰ National Cancer Center Hospital）：A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 81(6) : 1017-1023, 2018.
Natsume M¹, Watanabe K¹, Matsumoto S², Naruge D³, Hayashi K⁴, Furuse J, Kawamura M¹, Jinno H¹, Sano K¹, Fukushima R¹, Osawa G¹, Aruga E¹, Hashiguchi Y¹, Tanaka A¹, Takikawa H¹, Seki N¹（¹Teikyo University, ²NTT Medical Center Tokyo,³ Kyorin University, ⁴Tokyo Women’s Medical University）：Factors influencing cancer patients’ choice of end-of-life care place. J Palliat Med 21(6) : 751-765,2018.
Kojima Y¹, Ohtsuka K², Ohnishi H², Abe N¹, Furuse J, Watanabe T², Sugiyama M¹（¹ Department of Surgery, Kyorin University, ²Department of Laboratory Medicine, Kyorin Univeresity）：APC:T1556fs and STK11 mutations in duodenal adenomas and adenocarcinomas. Surg Today48(8) : 765-772, 2018.
Suzuki E¹, Kaneko S² Okusaka T³, Ikeda M⁴, Yamaguchi K⁵, Sugimoto R⁶, Aramaki T⁷, Asagi A⁸, Yasui K⁹, Sano K¹⁰, Hosokawa A¹¹, Kato N¹, Ishii H⁸, Sato T¹², Furuse J（¹Chiba University, ²Kanazawa University School of Medical Science, ³National Cancer Center Hospital, ⁴National Cancer Center Hospital East, ⁵Saitama Cancer Center,⁶Kyushu Cancer Center, ⁷Shizuoka Cancer Center, ⁸Shikoku Cancer Center,⁹Kyoto Prefectural University of Medicine, ¹⁰Teikyo University School of Medicine, ¹¹Faculty of Medicine University of Toyama, ¹²Kyoto University School of Public Health）: A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class. Jpn J Clin Oncol 48(4) : 317-321, 2018.
Nakachi K¹, Konishi M², Ikeda M², Mizusawa J³, Eba J³, Okusaka T³, Ishii H⁴, Fukuda H³, Furuse J (¹Otaru General Hospital, ²National Cancer Center Hospital East, ³National Cancer Center Hospital,⁴National Hospital Organization Shikoku Cancer Center)：Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group. A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Jpn J Clin Oncol 48(4) : 392-395, 2018.

J, Kurata T¹, Okano N, Fujisaka Y¹, Naruge D, Shimizu T¹, Kitamura H, Iwasa T¹, Nagashima F, Nakagawa K¹(¹Kindai University) : An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors. Cancer chemotherapy and pharmacology, 2018.

Sawaki M¹, Tamura K², Shimomura A², Taki Y¹, Nagashima F, Iwata H¹(¹Aichi Cancer Center Hospital, ²National Cancer Center Hospital) : Practice management for elderly patients with breast cancer: Findings from a survey by the Japan Breast Cancer Study Group. Nagoya Journal of Medical Science.80(2) : 217-26, 2018.
Yamaguchi K^1,2, Fujitani K³, Nagashima F, Omuro Y⁴, Machida N⁵, Nishina T⁶, Koue T⁷, Tsujimoto M⁷, (¹Saitama Cancer Center, ²Cancer Institute Hospital of Japanese Foundation for Cancer Research, ³Osaka General Medical Center, ⁴Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, ⁵Shizuoka Cancer Center,⁶National Hospital Organization Shikoku Cancer Center,⁷Eli Lilly Japan, ⁸Osaka University Hospital)：Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study. Gastric Cancer 21(6) : 1041-9, 2018.
Hamamoto Y^1,2, Sakakibara N¹, Nagashima F, Kitagawa Y³, Higashi T¹ (¹National Cancer Center, ²Keio Cancer Center,³Keio University School of Medicine)： Treatment selection for esophageal cancer: evaluation from a nationwide database. Esophagus15(2) : 109-14, 2018.
Sawaki M¹, Tamura K², Shimomura A², Taki Y¹, Nagashima F, Iwata H¹(¹Aichi Cancer Center Hospital, ²National Cancer Center Hospital)：Practice management for elderly patients with breast cancer: Findings from a survey by the Japan Breast Cancer Study Group. Nagoya Journal of Medical Science 80(2) : 217-26, 2018.
Furuse J, Kurata T¹, Okano N, Fujisaka Y¹, Naruge D, Shimizu T¹, Kitamura H, Iwasa T¹, Nagashima F¹, Nakagawa K(¹Kindai University Faculty of Medicine) : An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid Cancer Chemother Pharmacol.82(3):511-519, 2018.
Todaka A¹, Mizuno N², Ozaka M³, Ueno H⁴, Kobayashi S⁵, Uesugi K^6, Kobayashi N⁷, Hayashi H⁸, Sudo K⁹, Okano N, Horita Y¹⁰, Kamei K¹¹, Yukisawa S¹², Nakamori S¹³, Yachi Y¹⁴, Henmi T¹⁵, Kobayashi M^16, Boku N¹, Mori K¹, Fukutomi A¹(¹Shizuoka Cancer Center,²Aichi Cancer Center Hospital, ³The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, ⁴National Cancer Center Hospital, ⁵Kanagawa Cancer Center Hospital,⁶National Hospital Organization Shikoku Cancer Center, ⁷Yokohama City University Hospital, ⁸Hokkaido University Hospital, ⁹Chiba Cancer Center,¹⁰Toyama Prefectual Central Hospital,¹¹Kindai University Faculty of Medicine, ¹²Tochigi Cancer Center, ¹³Osaka National Hospital,¹⁴DaiichiSankyo, ¹⁵Yakult Honsha,¹⁶Shizuoka Industrial Foundation Pharama Vally Center)：Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Pancreas47(5):631-636, 2018. DOI: 10.1097/MPA.0000000000001049.
Yoshida T^1,2, Hijioka S^1,3, Hosoda W^1,4, Ueno M⁵, Furukawa M⁶, Kobayashi N⁷, Ikeda M⁸, Ito T⁹, Kodama Y¹⁰, Morizane C³, Notohara K¹¹, Taguchi H¹², Kitano M¹³, Yane K¹⁴, Tsuchiya Y¹⁵, Komoto I¹⁶, Tanaka H¹⁷, Tsuji A¹⁸, Hashigo S¹⁹, Mine T²⁰, Kanno A²¹, Murohisa G²², Miyabe K²³, Takagi T²⁴, Matayoshi N²⁵, Sakaguchi M²⁶, Ishii H²⁷, Kojima Y²⁸, Matsuo K²⁹, Yoshitomi H³⁰, Nakamori S³¹, Yanagimoto H³², Yatabe Y³³, Furuse J, Mizuno N¹ : (¹Aichi Cancer Center Hospital, ²Kizawa Memorial Hospital, ³National Cancer Center Hospital, ⁴The Johns Hopkins University School of Medicine,⁵Kanagawa Cancer Center, ⁶National Kyushu Cancer Center,⁷Yokohama City University Hospital, ⁸National Cancer Center Hospital East, ⁹Kyushu University, ¹⁰Kyoto University, ¹¹Kurashiki Central Hospital, ¹²Kagoshima University Graduate School of Medical and Dental Sciences, ¹³Kinki University, ¹⁴ Teine-Keijinkai Hospital, ¹⁵Niigata Cancer Center Hospital, ¹⁶Kansai Electric Power Hospital, ¹⁷Suzuka General Hospital, ¹⁸Kobe City Medical Center General Hospital, ¹⁹Kumamoto University, ²⁰Tokai University School of Medicine, ²¹Tohoku University Graduate School of Medicine, ²²Seirei Hamamatsu General Hospital, ²³Nagoya City University Graduate School of Medical Sciences, ²⁴Fukushima Medical University School of Medicine, ²⁵University of Occupational and Environmental Health, ²⁶Saiseikai Kumamoto Hospital, ²⁷Shikoku Cancer Center, ²⁸Cancer Institute Hospital, ²⁹Center Hospital of the National Center for Global Health and Medicine, ³⁰Aichi Cancer Center Research Institute, ³¹Chiba University, ³²National Hospital Organization Osaka National Hospital, ³³Kansai Medical University Hospital)：Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. Ann Surg Oncol. 26(5):1385-1393, 2019. DOI: 10.1245/s10434-019-07252-8. [Epub ahead of print]
Furuse J: A PARP inhibitor in pancreatic cancer : Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?. EBioMedicine2019. DOI: 10.1016/j.ebiom.2019.01.039.
Yasuda H¹, Kataoka K¹, Takeyama Y², Takeda K³, Ito T⁴, Mayumi T^5, Isaji S⁶, Mine T⁷, Kitagawa M⁸, Kiriyama S⁹, Sakagami J¹, Masamune A¹⁰, Inui K¹¹, Hirano K¹², Akashi R¹³, Yokoe M¹⁴, Sogame Y¹, Okazaki K¹⁵, Morioka C¹⁶, Kihara Y¹⁷, Kawa S¹⁸, Tanaka M⁴,Andoh A¹⁹, Kimura W²⁰, Nishimori I²¹, Furuse J, Yokota I²², Shimosegawa T¹⁰(¹Kyoto Prefectural University of Medicine,²Kindai University Faculty of Medicine, ³National Hospital Organization Sendai Medical Center, ⁴ Kyushu University, ⁵University of Occupational and Environmental Health, ⁶Mie University School of Medicine, ⁷Tokai University School of Medicine, ⁸Nagoya University of Arts and Sciences, ⁹Ogaki Municipal Hospital, ¹⁰Tohoku University Graduate School of Medicine, ¹¹Fujita Health University Bantane Hospital,¹²University of Tokyo, ¹³Kumamoto Regional Medical Center, ¹⁴Japanese Red Cross Nagoya Daini Hospital, ¹⁵Kansai Medical University, ¹⁶Nara Medical University, ¹⁷Kitakyushu General Hospital, ¹⁸Matsumoto Dental University, ¹⁹Shiga University of Medical Science, ²⁰Yamagata University Faculty of Medicine, ²¹Kochi Medical School,²²Hokkaido University)：Usefulness of urinary trypsinogen-2 and trypsinogen activation peptide in acute pancreatitis: A multicenter study in Japan. World J Gastroenterol 25(1) : 107-117, 2019.
Motoi F¹, Kosuge T², Ueno H², Yamaue H³, Satoi S⁴, Sho M⁵, Honda G⁶, Matsumoto I⁷, Wada K⁸, Furuse J, Matsuyama Y⁹, Unno M¹, Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP) (¹Tohoku University School of Medicine, ²National Cancer Center Hospital, ³Wakayama Medical University, ⁴Kansai Medical University, ⁵Nara Medical University, ⁶Tokyo Metropolitan Cancer and Infectious Diseases Center, ⁷Kindai University Faculty of Medicine,⁸Teikyo University School of Medicine,⁹University of Tokyo) : Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol 49(2) : 190-194, 2019.
Shitara K¹, Yamanaka T², Denda T³, Tsuji Y⁴, Shinozaki K⁵, Komatsu Y⁶, Kobayashi Y⁷, Furuse J, Okuda H⁸, Asayama M⁹, Akiyoshi K¹⁰, Kagawa Y¹¹, Kato T¹², Oki E¹³, Ando T¹⁴, Hagiwara Y¹⁵, Ohashi Y¹⁶, Yoshino T¹(¹National Cancer Center Hospital East,²Yokohama City University School of Medicine, ³Chiba Cancer Center, ⁴Tonan Hospital, ⁵Hiroshima Prefectural Hospital, ⁶Hokkaido University Hospital Cancer Center,⁷Kushiro Rosai Hospital, ⁸Keiyukai Sapporo Hospital, ⁹Saitama Cancer Center, ¹⁰Osaka City General Hospital, ¹¹Kansai Rosa Hospital, ¹²National Hospital Organization Osaka National Hospital, ¹³Kyushu University, ¹⁴University of Tsukuba, ¹⁵The University of Tokyo, ¹⁶Chuo University)：REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol 30(2) : 259-265, 2019.
Ioka T¹, Ueno M², Ueno H³, Park JO⁴, Chang HM⁵, Sasahira N⁶, Kanai M⁷, Chung IJ⁸, Ikeda M⁹, Nakamori S¹⁰, Mizuno N¹¹, Omuro Y¹², Yamaguchi T¹³, Hara H¹⁴, Sugimori K¹⁵, Furuse J, Maguchi H¹⁶, Furukawa M¹⁷, Fukuzawa K¹⁸, Kim JS¹⁹, Yukisawa S²⁰, Takeuchi M²¹, Okusaka T³, Boku N^3, Hyodo I²²(¹Osaka International Cancer Institute.²Kanagawa Cancer Center,³National Cancer Center Hospital, ⁴Sungkyunkwan University School of Medicine,⁵University of Ulsan College of Medicine, ⁶Cancer Institute Hospital of Japanese Foundation for Cancer Research, ⁷Kyoto University Hospital, ⁸Chonnam National University Hwasun Hospital, ⁹National Cancer Center Hospital East,¹⁰National Hospital Organization Osaka National Hospital, ¹¹Aichi Cancer Center Hospital, ¹²Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,¹³Chiba Cancer Center,¹⁴Saitama Cancer Center Hospital, ¹⁵Yokohama City University Medical Center, ¹⁶Teine-Keijinkai Hospital, ¹⁷National Hospital Organization Kyushu Cancer Center, ¹⁸Oita Red Cross Hospital, ¹⁹Korea University Guro Hospital, ²⁰Tochigi Cancer Center, ²¹ Kitasato University, ²² University of Tsukuba)：TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). Eur J Cancer 106 : 78-88, 2019.
Makishima H¹, Yasuda S¹, Isozaki Y¹, Kasuya G¹, Okada N¹, Miyazaki M², Mohamad O^1,3, Matsufuji N¹, Yamada S¹, Tsuji H¹, Kamada T¹, Liver Cancer Working Group (¹National Institute of Radiological Sciences Hospital, ²Mita Hospital, ³University of Texas Southwestern Medical center)：Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis: A dose escalation study. Cancer Sci 110(1) : 303-309,2019.
Denda T¹, Sakai D², Hamaguchi T³, Sugimoto N⁴, Ura T⁵, Yamazaki K⁶ Fujii H⁷, Kajiwara T⁸, Nakajima TE⁹, Takahashi S¹⁰, Otsu S¹¹, Komatsu Y¹², Nagashima F, Moriwaki T¹³, Esaki T¹⁴, Sato T¹⁵, Itabashi M¹⁶, Oki E¹⁷, Sasaki T¹⁸, Sunaga Y¹⁸, Ziti-Ljajic S¹⁹, Brillac C¹⁹, Yoshino T²⁰(¹Chiba Cancer Center, ² Osaka University Graduate School of Medicine, ³ National Cancer Center Hospital, ⁴Osaka Medical Center for Cancer and Cardiovascular Disease,⁵Aichi Cancer Center Hospital, ⁶Shizuoka Cancer Center, ⁷Jichi Medical University Hospital, ⁸Shikoku Cancer Center, ⁹ Marianna University School of Medical Hospital, ¹⁰Tohoku University Hospital, ¹¹Oita University Hospital, ¹²Hokkaido University Hospital, ¹³University of Tsukuba Hospital, ¹⁴National Kyushu Cancer Center, ¹⁵Kitasato University East Hospital, ¹⁶Tokyo Women’s Medical University Hospital, ¹⁷Kyushu University Hospital, ¹⁸Sanofi K. K, ¹⁹Sanofi Oncology,²⁰National Cancer Center Hospital East) : Phase II trial of aflibercept with FOLFIRI as a second-line treatment , for Japanese patients with metastatic colorectal cancer. Cancer science, 2019.
Shirasu H1, Todaka A1, Omae K2, Fujii H3, Mizuno N4, Ozaka M5, Ueno H6, Kobayashi S7, Uesugi K8, Kobayashi N9, Hayashi H10, Sudo K11, Okano N, Horita Y12, Kamei K13, Yukisawa S14, Kobayashi M15, Fukutomi A16 (1Shizuoka Cancer Center, 2Jichi Medical University Hospital, 3Aichi Cancer Center Hospital, 4The Cancer Institute Hospital of the Japanese Foundation For Cancer Research, 5National Cancer Center Hospital, 6Kanagawa Cancer Center, 7 National Hospital Organization Shikoku Cancer Center, 8Yokohama City University Hospital, 9 Hokkaido University Graduate School of Medicine, 10Chiba Cancer Center, 11Toyama Prefectural Central Hospital, 12 Kindai University, 13Tochigi Cancer Center, 14 Shizuoka Industrial Foundation Pharma Valley Center) : Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Cancer Sci110(2) : 707-716, 2019. DOI: 10.1111, /cas.13883.

和文

北村浩¹, 井戸田一朗¹, 岡山香里², 大河戸光章³, 佐野彰彦⁴, 佐野麻里子⁵, 小林治⁶, 河合伸⁴, 古瀬純司 (¹しらかば診療所,²群馬バース大・保・検査技術学, ³杏林大・保・臨床検査技術学, ⁴杏林大・医・総合医療学・⁵杏林大・医学部付属病院看護部, ⁶杏林大・保) : 拡大肛門鏡検査によるHIV陽性者の肛門管上皮内病変の診断と治療. 日本エイズ学会誌 20(1) : 25-31, 2018.
古瀬純司 : 切除不能膵癌に対する化学療法. 消化器外科 41(6):911-917, 2018.
古瀬純司 : 化学療法. 膵癌臨牀消化器内科 33(7):167-173, 2018.
古瀬純司 : 切除不能膵癌に対する化学療法―現状と今後の展望. 癌の臨床 64(1) : 17-23, 2018.
古瀬純司 : 膵癌の治療. 化学療法と化学放射線療法. Current Therapy 36(6):23-28, 2018.
古瀬純司 : 急激に変貌する肝癌の薬物療法.免疫チェックポイント阻害薬（単剤）. Liver Cancer Journal 10(1):44-48, 2018.
古瀬純司 : 膵神経内分泌腫瘍の化学療法. 臨牀消化器内科 33(9):1177-1182, 2018.
古瀬純司 : 進行肝細胞癌に対する分子標的治療のオーバービュー. 消化器・肝臓内科 4(1):37-43, 2018.
古瀬純司 : Cabozantinibの第II相試験の振り返りと第III総試験結果. 肝胆膵 77(2):393-397, 2018.
古瀬純司 : ソラフェニブ不応進行肝細胞癌に対するレゴラフェニブの第Ⅲ相試験（RESORCE）の示唆すること. がん分子標的治療 16(3):78-81, 2018.
山内芳也, 長島文夫, 河合桐男, 岡野尚弘, 成毛大輔, 小林敬明, 古瀬純司：高齢がん患者の機能評価. 外科と代謝・栄養 52(1):17-22, 2018.
小林敬明, 前野聡子, 長島文夫：高齢者のがん診療〜実地医家の視点から〜胃がん・大腸がん. 内科 121(4):887-891, 2018.
前野聡子, 長島文夫：がんとフレイル. 最新医学　別冊(フレイル):107-112, 2018.
前野聡子, 長島文夫：老年医学領域の高度医療・未来医療　高齢者のがん医療の進歩. 日本臨床76(増刊5 老年医学(上)):255-259, 2018.
岡野尚弘, 黒澤貴志, 西岡真理子, 前園知宏, 河合桐男, 小林敬明,長島文夫, 古瀬純司 : 切除不能胆道癌に対する二次治療　現状と今後の期待. 胆と膵39(10):869-874, 2018.
黒澤貴志, 前野聡子, 長島文夫：後期高齢者に対するがん薬物治療の問題点. 臨床腫瘍プラクティス 14(4):241-248, 2018.
長島文夫, 小林智¹, 柳本泰明², 中井陽介³(¹神奈川県立がんセンター・消化器内科, ²関西医大・医・外科学講座,³東京大・医・消化器内科)：膵・胆道癌高齢患者に対する積極的抗癌治療. 膵・胆道癌Frontier 7(2):64-71, 2018.
黒澤貴志, 岡野尚弘, 長島文夫, 古瀬純司 : 胆嚢癌の治療. 消化器内科 34(2):193-198, 2019.
古瀬純司 : 膵癌の予後改善に向けて. 医学のあゆみ 268(11):893, 2019.
岡野尚弘, 西岡真理子, 前園知宏, 黒澤貴志, 河合桐男, 小林敬明, 長島文夫, 古瀬純司 : 大腸がん化学療法の最近の潮流. 消化器・肝臓内科 5(1):1-9, 2019.
岡野尚弘：41st ESMO Congress 2016. 膵胆道癌FRONTIER 7(1):43-44, 2019.
岡野尚弘：切除不能膵癌に対するconversion surgery. 医学のあゆみ268(11):913-916, 2019.
前野聡子, 河合桐男, 黒澤貴志, 西岡真理子, 前園知宏, 北村浩, 小林敬明, 岡野尚弘, 長島文夫, 古瀬純司 : 高齢者に対する大腸癌化学療法の実際. 消化器・肝臓内科5(1):17-23, 2019.
前野聡子,長島文夫：高齢がん診療のあり方. Geriatric　Neurosurgery31：19-22, 2019.

著書

河合桐男,古瀬純司（分担執筆）: IV.　薬剤のマネージメントエベロリムス. 膵・消化管NETの診断と治療レジメン―治療に困った時に必ず役に立つ！―. 肱岡範, 奥坂拓志編集. 東京, 医学と看護社, 2018. p.92-96.
古瀬純司（分担執筆）:　肝癌, 胆道癌, 膵癌化学療法の最近の動向. エビデンスに基づいた癌化学療法ハンドブック大津敦編集. 大阪, メディカルレビュー社, 2018. p.478-490.

岡野尚弘（分担執筆）: 膵癌　エビデンスに基づいた癌化学療法ハンドブック2018. 大津敦編集. 大阪, メディカルレビュー社, 2018. p.511-513
岡野尚弘（分担執筆）: 膵癌　GEM＋Nab-PTX. エビデンスに基づいた癌化学療法ハンドブック大津敦編集. 大阪, メディカルレビュー社, 2018. p.514-516
岡野尚弘（分担執筆）: 膵癌　GEM＋エビデンスに基づいた癌化学療法ハンドブック2018. 大津敦編集. 大阪, メディカルレビュー社, 2018. p.521-523
岡野尚弘（分担執筆）：大腸癌　UFT＋消化器がん化学療法レジメンブック4版. 室圭編著. 東京, 日本医事新報社, 2018. p.191-193.
岡野尚弘（分担執筆）：大腸癌　IRI＋S-1/IRIS療法＋ベバシズマブ. 消化器がん化学療法レジメンブック4版. 室圭編著. 東京, 日本医事新報社, 2018. p.194-197.
古瀬純司（分担執筆）: ガイドライン外来診療膵癌. 東京, 日経メディカル開発, 2019. p.585-589.
古瀬純司（編者）: がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 大阪, メディカ出版，
古瀬純司（編者）: 膵癌の予後改善に向けて.医学のあゆみ.東京,医歯葉出版, 268(11), 2019
古瀬純司（編者）: 神経内分泌腫瘍の薬物療法.東京, 科学評論社, 23(3), 2019
岡野尚弘（分担執筆）: レゴラフェニブ. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.58-59.
岡野尚弘（分担執筆）: バンデタニブ. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.60-61.
岡野尚弘（分担執筆）: ゲムシタビン.化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.142-143.
岡野尚弘（分担執筆）: パクリタキセル. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.230-231.
岡野尚弘（分担執筆）: ナブパクリタキセル. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.232-233.
岡野尚弘（分担執筆）: ドセタキセル. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.234-235.

講 演

論 文

著 書

報告書

その他

講 演

論 文

著 書

報告書

その他

講 演

論 文

著書

講　演

論　文

著　書

講　演

論　文

著　書

講　演

論　文